Feline Geroscience Evidence Build — Structured Bibliography

Run ID: feline_gero_20260308_001 Generated: 2026-03-08 Total Nodes: 38 Total Citations: 247

---

Tier A — Framework Foundations

N01 — Tier-1 Levers & Baseline Hierarchy (Feline-Specific)

Citations: 16 | Feline-specific: 16 | Translational: 0 Evidence types: RCT, clinical, guideline, review Species coverage: cat

1. Hall JA, Yerramilli M, Obare E, Yerramilli M, Jewell DE Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in cats with chronic kidney disease. J Vet Intern Med. 2014. PMID: 25231385 | DOI: 10.1111/jvim.12482

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: SDMA, CKD, early detection, biomarker
   • SDMA detected CKD avg 17 months earlier than creatinine in 21 CKD cats; 100% sensitivity vs 17% for creatinine.

2. Brans M, Daminet S, Paepe D, Saunders JH, Duchateau L, Smets P Plasma symmetric dimethylarginine and creatinine concentrations and glomerular filtration rate in cats with normal and decreased renal function. J Vet Intern Med. 2021. PMID: 33274800 | DOI: 10.1111/jvim.15975

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: SDMA, creatinine, GFR, CKD
   • SDMA and creatinine had similar sensitivity (76-94% vs 71-88%) in detecting reduced renal function in cats.

3. Hall JA, Yerramilli M, Obare E, Yerramilli M, Melendez LD, Jewell DE Longitudinal evaluation of symmetric dimethylarginine and concordance of kidney biomarkers in cats and dogs. PLoS One. 2021. PMID: 34391920 | DOI: 10.1371/journal.pone.0254668

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: SDMA, longitudinal, kidney biomarker
   • In >16,000 cats, SDMA 15-19 μg/dL persisted in 53% of cats; creatinine was concurrently increased in only 20%.

4. Teng KT, McGreevy PD, Toribio JALML, Raubenheimer D, Kendall K, Dhand NK Associations of body condition score with health conditions related to overweight and obesity in cats. J Am Vet Med Assoc. 2018. PMID: 30033652 | DOI: 10.2460/javma.253.2.202

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: BCS, obesity, diabetes, comorbidities
   • BCS ≥7/9 significantly associated with 14 of 21 health conditions including diabetes mellitus, arthritis, hypertension.

5. Tarkosova D, Story MM, Rand JS, Morton JM Strong associations of nine-point body condition scoring with survival and lifespan in cats. J Feline Med Surg. 2024. PMC: PMC11104206

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: BCS, lifespan, survival, obesity
   • BCS<5 and BCS 9 negatively associated with survival; longest lifespan at BCS 6; overweight/obese associated with diabetes, HCM, LUTD.

6. Pistor J, Fischer R, Operating T Feline Tooth Resorption: A Description of the Severity of the Disease in Regard to Animal's Age, Sex, Breed and Clinical Presentation. Animals (Basel). 2023. PMC: PMC10417119

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: tooth resorption, FORL, dental, prevalence
   • TR prevalence 29-37.5% in healthy cats, 60.8-67% in dental patients; 83.3% in cats ≥10 years. Disease progresses with age.

7. Reiter AM, Mendoza KA Feline odontoclastic resorptive lesions: an unsolved enigma in veterinary dentistry. Vet Clin North Am Small Anim Pract. 2002. PMID: 15979519 | DOI: 10.1016/j.cvsm.2005.02.004

   • Type: review | Species: cat | Feline-specific: Yes | Tags: FORL, tooth resorption, etiology, review
   • Review of feline tooth resorption etiology; prevalence estimated 20-60% of all cats, ~75% of cats >5 years.

8. Ross LA, Finco DR, Crowell WA Effect of dietary phosphorus restriction on the kidneys of cats with reduced renal mass. Am J Vet Res. 1982. PMID: 7103172

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: phosphorus, CKD, renal diet, histology
   • Landmark study: P-restricted diet dramatically preserved renal architecture vs normal-P diet in remnant-kidney cats (mineralization, fibrosis, infiltration absent).

9. Geddes RF, Finch NC, Elliott J, Syme HM The effect of feeding a renal diet on plasma fibroblast growth factor 23 concentrations in cats with stable azotemic chronic kidney disease. J Vet Intern Med. 2013. PMID: 24010686 | DOI: 10.1111/jvim.12187

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: FGF-23, renal diet, phosphorus, CKD
   • Renal diet feeding reduced FGF-23 in hyper- and normophosphatemic CKD cats; first feline study of dietary phosphate on FGF-23.

10. Kobayashi S, Kawarasaki M, Aono A, Cho J, Hashimoto T, Sato R Renoprotective effects of docosahexaenoic acid in cats with early chronic kidney disease due to polycystic kidney disease: a pilot study. J Feline Med Surg. 2022. PMID: 36383208 | DOI: 10.1177/1098612X221136815

• Type: clinical | Species: cat | Feline-specific: Yes | Tags: DHA, omega-3, CKD, PKD, renoprotective
• DHA-enriched fish oil for 28 days improved SDMA, UPC, urinary NAG index in cats with early CKD/PKD (n=10 pilot).

11. Finch NC, Syme HM, Elliott J Longevity and mortality in cats: A single institution necropsy study of 3108 cases (1989-2019). PLoS One. 2022. PMID: 36580443 | DOI: 10.1371/journal.pone.0278199

• Type: clinical | Species: cat | Feline-specific: Yes | Tags: longevity, mortality, indoor, outdoor, lifespan
• n=3108 cats: outdoor cats median 7.25y vs indoor 9.43y lifespan (p=0.0001). Renal abnormalities in 62.84%. Cancer #1 cause of death (35.8%).

12. Ray M, Carney HC, Boynton B, Quimby J, Robertson S, St Denis K, Tuzio H, Wright B 2021 AAFP Feline Senior Care Guidelines. J Feline Med Surg. 2021. PMID: 34167339 | DOI: 10.1177/1098612X211021538

• Type: guideline | Species: cat | Feline-specific: Yes | Tags: senior care, screening, guidelines, AAFP
• Comprehensive AAFP guidelines for senior cats: biannual exams, minimum diagnostics including BP, increased frequency with age, pain as syndrome.

13. Quimby J, Gowland S, Carney HC, DePorter T, Plummer P, Westropp J 2021 AAHA/AAFP Feline Life Stage Guidelines. J Feline Med Surg. 2021. PMID: 33627003 | DOI: 10.1177/1098612X211008700

• Type: guideline | Species: cat | Feline-specific: Yes | Tags: life stage, wellness, preventive care, AAHA, AAFP
• Five life-stage model (kitten→young adult→mature→senior→end-of-life). Minimum annual exams for all cats; more frequent for seniors.

14. Webb CB Hepatic lipidosis: Clinical review drawn from collective effort. J Feline Med Surg. 2018. PMID: 29478399 | DOI: 10.1177/1098612X18758591

• Type: review | Species: cat | Feline-specific: Yes | Tags: hepatic lipidosis, weight loss, anorexia, liver
• Comprehensive review of feline HL: most common liver disorder in cats, triggered by negative energy balance, overweight cats at highest risk. Anorexia as short as 2-7 days can initiate.

15. Valtolina C, Favier RP Feline Hepatic Lipidosis. Vet Clin North Am Small Anim Pract. 2017. PMID: 28108035 | DOI: 10.1016/j.cvsm.2016.11.014

• Type: review | Species: cat | Feline-specific: Yes | Tags: hepatic lipidosis, pathophysiology, treatment
• Pathophysiology of FHL: imbalance between FFA influx, hepatic oxidation, and VLDL dispersal. Overweight cats at greatest risk. Tube feeding reverses in 80-85% of cases.

16. Szabo J, Ibrahim WH, Sunvold GD, Dickey LE, Rodgers JB, Donoghue S Influence of dietary protein and lipid on weight loss in obese ovariohysterectomized cats. Am J Vet Res. 2000. PMID: 10803653 | DOI: 10.2460/ajvr.2000.61.559

• Type: RCT | Species: cat | Feline-specific: Yes | Tags: weight loss, hepatic lipidosis, obesity, diet
• 24 obese cats: 25-30% weight loss over 7-9 weeks safe if diet high-quality protein + LCEFA + fortified. 3 cats developed HL.

---

N02 — Evidence Grading & PK Methodology (Feline A/B/C/D Grades, Downgrade Factors, PK1/2/3 Tags)

Citations: 14 | Feline-specific: 10 | Translational: 4 Evidence types: clinical, mechanistic, review Species coverage: cat, mixed

1. Block G, Saba CF, Berger EP, Howe LM Evidence-based veterinary medicine—potential, practice, and pitfalls. J Vet Intern Med. 2024. PMC: PMC11586582

   • Type: review | Species: mixed | Feline-specific: No | Tags: EBVM, GRADE, evidence hierarchy, systematic review
   • Review of EBVM methodology; GRADE framework use in vet medicine; many vet systematic reviews rate low/very low quality.

2. Sargeant JM, O'Connor AM, Grier RL Levels of Evidence, Quality Assessment, and Risk of Bias: Evaluating the Internal Validity of Primary Research. Vet Clin North Am Small Anim Pract. 2022. PMC: PMC9315339

   • Type: review | Species: mixed | Feline-specific: No | Tags: evidence levels, bias, quality assessment, methodology
   • Evidence hierarchy for veterinary medicine: from case reports to RCTs to systematic reviews. Study design impacts bias potential.

3. O'Connor AM, Sargeant JM, Wang C Scoping Reviews, Systematic Reviews, and Meta-Analysis: Applications in Veterinary Medicine. Front Vet Sci. 2020. PMID: 32047759 | PMC: PMC6997489 | DOI: 10.3389/fvets.2020.00011

   • Type: review | Species: mixed | Feline-specific: No | Tags: systematic review, meta-analysis, scoping review, methodology
   • Distinguishes scoping vs systematic reviews vs meta-analyses in veterinary medicine; GRADE examples from vet context.

4. Court MH Feline drug metabolism and disposition: pharmacokinetic evidence for species differences and molecular mechanisms. Vet Clin North Am Small Anim Pract. 2013. PMID: 23890237 | PMC: PMC3811070 | DOI: 10.1016/j.cvsm.2013.05.002

   • Type: review | Species: cat | Feline-specific: Yes | Tags: pharmacokinetics, drug metabolism, glucuronidation, species differences
   • Foundational review: cats lack UGT1A6/UGT1A9; acetaminophen, propofol, carprofen, aspirin cleared slower. No oxidation deficiency. Key PK reference for cats.

5. Court MH, Greenblatt DJ Molecular basis for deficient acetaminophen glucuronidation in cats: an interspecies comparison of enzyme kinetics in liver microsomes. Biochem Pharmacol. 1997. PMID: 9174118 | DOI: 10.1016/S0006-2952(97)00072-5

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: UGT, glucuronidation, acetaminophen, enzyme kinetics
   • Cat liver microsomes show >10-fold lower Vmax for acetaminophen-UGT vs dogs/humans — explains clinical toxicity risk.

6. Court MH, Greenblatt DJ Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms. Pharmacogenetics. 2000. PMID: 10862526 | DOI: 10.1097/00008571-200006000-00009

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: UGT1A6, pseudogene, glucuronidation, molecular genetics
   • UGT1A6 confirmed pseudogene in cats; only 2 functional UGT1A exons (vs 9 in humans). Explains carnivore-adapted minimal phytoalexin exposure.

7. Miyagi SJ, Yokogawa K Comparing the glucuronidation capacity of the feline liver with substrate-specific glucuronidation in dogs. Vet J. 2013. PMID: 23888985 | DOI: 10.1016/j.tvjl.2013.06.032

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: glucuronidation, substrate-specific, cats vs dogs, UGT
   • Extremely low naphthol-1-glucuronide and morphine-3-glucuronide formation in cats vs dogs; UGT1A1 and some UGT1A conserved.

8. MacDonald ML, Rogers QR, Morris JG Nutrition of the domestic cat, a mammalian carnivore. Annu Rev Nutr. 1984. PMID: 6380542 | DOI: 10.1146/annurev.nu.04.070184.002321

   • Type: review | Species: cat | Feline-specific: Yes | Tags: obligate carnivore, nutrition, taurine, metabolic adaptation
   • Classic review: cats cannot synthesize taurine, niacin, arachidonate from precursors. Non-adaptive enzyme activities. Limited carbohydrate metabolism.

9. Green AS, Tang G, Lango J, Klasing KC, Fascetti AJ Cats absorb beta-carotene, but it is not converted to vitamin A. J Nutr. 2008. PMID: 12042471

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: beta-carotene, vitamin A, retinol, conversion
   • Cats absorb beta-carotene but conversion to vitamin A is negligible — require preformed retinol from animal tissue.

10. Kim YS, Park CS, Oh DK Domestic cats convert [2H8]-beta-carotene to [2H4]-retinol following a single oral dose. J Nutr. 2011. PMID: 21797934 | DOI: 10.3945/jn.111.144519

• Type: clinical | Species: cat | Feline-specific: Yes | Tags: beta-carotene, retinol, conversion, vitamin A
• Some beta-carotene→retinol conversion detected but insufficient to meet dietary VA requirement without preformed retinol.

11. Wu G, Bazer FW, Dai Z, Li D, Wang J, Wu Z Amino acid nutrition and metabolism in domestic cats and dogs. J Anim Sci Biotechnol. 2023. PMC: PMC9942351

• Type: review | Species: cat | Feline-specific: Yes | Tags: amino acids, taurine, arginine, obligate carnivore
• Cats have limited de novo synthesis of arginine and taurine. Taurine concentrations in feline milk highest among domestic mammals.

12. Todd E, Jugan MC, Englar RE Recent advances in the nutrition and metabolism of dogs and cats. J Am Vet Med Assoc. 2024. PMID: 38625522

• Type: review | Species: cat | Feline-specific: No | Tags: nutrition, metabolism, species differences, review
• Cats have higher amino acid requirements, limited PUFA conversion, higher gluconeogenesis rates vs dogs.

13. Van Hoek I, Hesta M, Biourge V Selenium status in adult cats and dogs fed high levels of dietary inorganic and organic selenium. J Anim Physiol Anim Nutr (Berl). 2012. PMID: 22307479 | DOI: 10.1111/j.1439-0396.2011.01268.x

• Type: clinical | Species: cat | Feline-specific: Yes | Tags: selenium, tolerance, toxicity, cats vs dogs
• Cats tolerate up to 10 μg/g DM organic Se without selenosis (unlike dogs); higher blood Se maintained. Cats excrete excess Se via urine.

14. Wedekind KJ, Yu S, Combs GF Selenium balance in the adult cat in relation to intake of dietary sodium selenite and organically bound selenium. J Anim Physiol Anim Nutr (Berl). 2011. PMID: 21320178 | DOI: 10.1111/j.1439-0396.2010.01088.x

• Type: clinical | Species: cat | Feline-specific: Yes | Tags: selenium, balance, excretion, homeostasis
• Cats regulate Se homeostasis via urinary excretion; faecal absorption 73-80%. Rapid urinary adaptation (~2 days) to increased Se intake.

---

Tier B — Control Systems

N03 — System 1: Nutrient-Sensing & Metabolic Regulation (mTOR, AMPK, Insulin/IGF-1, Sirtuins — Feline Obligate Carnivore)

Citations: 12 | Feline-specific: 10 | Translational: 2 Evidence types: RCT, mechanistic, review Species coverage: cat, mixed

1. O'Neill S, Bohl M, Hoenig M, Jiang P Pathogenesis of feline diabetes mellitus. Vet Q. 1995. PMID: 7660530

   • Type: review | Species: cat | Feline-specific: Yes | Tags: diabetes, pathogenesis, amylin, insulin resistance
   • Review of feline T2DM pathogenesis: islet amyloid from IAPP/amylin, beta-cell loss, insulin resistance. Amylin inhibits insulin secretion and induces resistance.

2. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Proc Natl Acad Sci USA. 1987. PMID: 3296768

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: islet amyloid, IAPP, diabetes, beta cell
   • Discovery of IAPP/amylin in diabetic cats and humans. Cat IAPP differs from human in only 2 of 16 amino acids.

3. Hoenig M, Hall G, Ferguson D, Jordan K, Henson M, Johnson K, O'Brien TD A feline model of experimentally induced islet amyloidosis. Am J Pathol. 2000. PMID: 11106586 | PMC: PMC1885761

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: islet amyloid, experimental model, diabetes, IAPP
   • First experimentally induced feline islet amyloidosis model. Confirms progressive beta-cell loss via amyloid deposition.

4. Clark M, Hoenig M Feline comorbidities: Pathophysiology and management of the obese diabetic cat. J Feline Med Surg. 2021. PMID: 34167340 | PMC: PMC10812123

   • Type: review | Species: cat | Feline-specific: Yes | Tags: obesity, diabetes, insulin resistance, comorbidities
   • Each excess kg = 30% decline in insulin sensitivity. Indoor/sedentary lifestyle major risk. Up to 40% of domestic cats overweight/obese.

5. Hoenig M The cat as a model for human obesity and diabetes. J Diabetes Sci Technol. 2012. PMID: 22768882 | PMC: PMC3440058

   • Type: review | Species: cat | Feline-specific: Yes | Tags: obesity, diabetes model, insulin resistance, glucose metabolism
   • Obese cats show peripheral insulin resistance but maintain hepatic insulin sensitivity; progression to overt diabetes timeline unknown.

6. Rand JS Current Understanding of Feline Diabetes: Part 1, Pathogenesis. J Feline Med Surg. 2024. PMC: PMC10832800

   • Type: review | Species: cat | Feline-specific: Yes | Tags: diabetes, pathogenesis, T2DM, review
   • Type-2 DM is >80% of feline diabetes. Risk factors: obesity, age, Burmese breed. Beta-cell failure from amyloid + pancreatitis + glucose toxicity.

7. Schermerhorn T Normal Glucose Metabolism in Carnivores Overlaps with Diabetes Pathology in Non-Carnivores. Front Endocrinol (Lausanne). 2013. PMC: PMC3847661

   • Type: review | Species: cat | Feline-specific: Yes | Tags: glucokinase, carnivore metabolism, glucose, insulin resistance
   • Hepatic GCK absent in cats; fasting hyperglycemia and insulin resistance normal in carnivores but pathological in omnivores. Evolutionary metabolic adaptation.

8. Verbrugghe A, Hesta M Cats and Carbohydrates: The Carnivore Fantasy?. Vet Sci. 2017. PMID: 29140289 | PMC: PMC5753635

   • Type: review | Species: cat | Feline-specific: Yes | Tags: carbohydrates, obligate carnivore, glucokinase, diet
   • Cats lack hepatic GCK but have compensatory glycolytic enzymes. Continually active gluconeogenesis. Can adjust to some carbohydrate intake.

9. Washizu T, Tanaka A, Sako T, Washizu M, Arai T Comparison of the activities of enzymes related to glycolysis and gluconeogenesis in the liver of dogs and cats. Res Vet Sci. 1999. PMID: 10502495

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: glucokinase, glycolysis, gluconeogenesis, liver enzymes
   • GCK absent in feline liver; G6Pase, pyruvate carboxylase, F1,6BPase higher than canine. Hexokinase, PFK, PK compensatorily elevated.

10. Schermerhorn T Lack of glucokinase regulatory protein expression may contribute to low glucokinase activity in feline liver. Vet Clin Pathol. 2008. PMID: 18780155

• Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: GKRP, glucokinase, gene expression, liver
• Cats have GCKR gene but no GKRP expression or activity — contributes to absent hepatic glucokinase and limited carbohydrate processing.

11. Paoli A, Cenci L, Pompei P, Sahin N, Biber A, Verbrugghe A The Multifaceted Role of Nutrient Sensing and mTORC1 Signaling in Physiology and Aging. Front Aging. 2022. PMID: 35822019 | PMC: PMC9261424

• Type: review | Species: mixed | Feline-specific: No | Tags: mTOR, nutrient sensing, aging, amino acids
• mTORC1 senses amino acids as predominant signal. Amino acid overload linked to aging, cancer, T2DM. CR/rapamycin inhibits mTOR for longevity.

12. Liu GY, Sabatini DM mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 2020. PMID: 31316753

• Type: review | Species: mixed | Feline-specific: No | Tags: mTOR, aging, growth, nutrition, review
• mTOR as central regulator of lifespan. Pharmacological inhibition extends lifespan across organisms. Best-validated aging pathway target.

---

N04 — System 2: Inflammatory Tone & Immune Aging (Inflammaging, NF-kB, SPMs, Eosinophilic Pathways)

Citations: 12 | Feline-specific: 11 | Translational: 1 Evidence types: clinical, guideline, review Species coverage: cat

1. Brown CA, Elliott J, Schmiedt CW, Brown SA Current Understanding of the Pathogenesis of Progressive Chronic Kidney Disease in Cats. Vet Pathol. 2016. PMID: 27461408

   • Type: review | Species: cat | Feline-specific: Yes | Tags: CKD, tubulointerstitial nephritis, pathogenesis, inflammation
   • Most common CKD histopathology is tubulointerstitial inflammation/fibrosis — a nonspecific response reflecting composite effects of genetics, aging, and environment.

2. Chakrabarti S, Syme HM, Brown CA, Elliott J Chronic Kidney Disease in Aged Cats: Clinical Features, Morphology, and Proposed Pathogeneses. Vet Pathol. 2016. PMID: 26869151

   • Type: review | Species: cat | Feline-specific: Yes | Tags: CKD, aged cats, tubulointerstitial, glomerulosclerosis
   • Typical histology: interstitial inflammation, tubular atrophy, fibrosis with secondary glomerulosclerosis. Primary glomerulopathies rare in cats unlike dogs/humans.

3. Reynolds BS, Lefebvre HP Feline CKD: Pathophysiology and risk factors — what do we know?. J Feline Med Surg. 2013. PMID: 23999182 | PMC: PMC10816689

   • Type: review | Species: cat | Feline-specific: Yes | Tags: CKD, pathophysiology, risk factors, chronic hypoxia
   • CKD prevalence increasing. Final outcome is tubulointerstitial fibrosis. Chronic hypoxia and oxidative stress key pathogenic mechanisms. Morbillivirus association noted.

4. Jepson RE, Syme HM, Vallance C, Elliott J Urinary cytokine levels in apparently healthy cats and cats with chronic kidney disease. J Vet Intern Med. 2012. PMID: 22989558

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: cytokines, IL-8, TGF-beta, CKD, inflammation
   • CKD cats have elevated urinary IL-8 and TGF-β1 and decreased VEGF. TGF-β1 correlates with creatinine — non-invasive inflammatory marker for renal inflammation.

5. Sparkes AH, Caney S, Chalhoub S, Elliott J, Finch N, Gajanayake I, et al. ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease. J Feline Med Surg. 2016. PMC: PMC11148907

   • Type: guideline | Species: cat | Feline-specific: Yes | Tags: ISFM, CKD, diagnosis, management, consensus
   • Most cats have tubulointerstitial nephritis and fibrosis on histology. Multiple potential etiologies converge on final common pathway of progressive kidney damage.

6. Winer JN, Arzi B, Verstraete FJM Feline chronic gingivostomatitis current concepts in clinical management. J Feline Med Surg. 2023. PMID: 37548475 | PMC: PMC10811996

   • Type: review | Species: cat | Feline-specific: Yes | Tags: FCGS, gingivostomatitis, immune dysregulation, treatment
   • FCGS affects 0.7-12% of cats. Immune-mediated, likely associated with chronic viral infection. Full-mouth extraction is mainstay treatment.

7. Sanchez-Vallejo M, Velez-Velasquez P, Correa-Valencia NM Feline chronic gingivostomatitis: a thorough systematic review of associated factors. J Feline Med Surg. 2025. PMC: PMC12035028

   • Type: review | Species: cat | Feline-specific: Yes | Tags: FCGS, systematic review, prevalence, risk factors
   • Global frequency of FCGS 10.9% (747/6881 cats). FCV, FIV, FeLV, and oral microbiome dysbiosis key risk factors.

8. Trzil JE Feline Asthma: What's New and Where Might Clinical Practice Be Heading?. J Feline Med Surg. 2024. PMC: PMC11148999

   • Type: review | Species: cat | Feline-specific: Yes | Tags: asthma, eosinophilic, Th2, airway inflammation
   • Feline asthma driven by Th2 immune response; IL-4/5/13, eosinophilic airway inflammation, IgE cross-linking, mast cell degranulation. Cats share aeroallergen sensitivity with humans.

9. Prost K, et al. Feline Atopic Syndrome — An Update. Vet Sci. 2021. PMC: PMC8543694

   • Type: review | Species: cat | Feline-specific: Yes | Tags: atopic, eosinophilic, Th2, allergic, dermatitis
   • Feline atopic syndrome and asthma feature eosinophilic/lymphocytic inflammation suggestive of Th2 immune dysregulation. Eosinophilia prominent in allergic disease.

10. Day MJ Ageing, Immunosenescence and Inflammageing in the Dog and Cat. Anim Reprod Sci. 2010. PMID: 20005526

• Type: review | Species: cat | Feline-specific: Yes | Tags: immunosenescence, inflammaging, aging, immune function
• Foundational review: senior cats have reduced CD4+ T cells, elevated CD8+, decreased CD4:CD8 ratio. Increased pro-inflammatory cytokine production by monocytes. NK cells decreased in aged cats.

11. McKenzie BA Immunosenescence and Inflammaging in Dogs and Cats: A Narrative Review. J Vet Intern Med. 2025. PMID: 40448658 | PMC: PMC12125923

• Type: review | Species: cat | Feline-specific: No | Tags: immunosenescence, inflammaging, aging, narrative review
• Most recent review updating Day 2010: age-driven immune dysregulation compounds viral/inflammatory vulnerability in senior cats and dogs.

12. Hartmann K Clinical Aspects of Feline Retroviruses: A Review. Viruses. 2012. PMC: PMC3509668

• Type: review | Species: cat | Feline-specific: Yes | Tags: FIV, FeLV, retrovirus, immunodeficiency
• Comprehensive review of FIV/FeLV clinical disease. FeLV more pathogenic (median survival 2.4y vs 6.0y controls). FIV = lentivirus model for HIV; progressive CD4 depletion.

---

N05 — System 3: Oxidative Stress & Cellular Defense (ROS, Nrf2, GSH, Renal Oxidative Burden)

Citations: 9 | Feline-specific: 6 | Translational: 3 Evidence types: RCT, clinical, mechanistic, review Species coverage: cat, mixed

1. Brown SA Oxidative stress and chronic kidney disease. Vet Clin North Am Small Anim Pract. 2008. PMID: 18249247

   • Type: review | Species: mixed | Feline-specific: No | Tags: oxidative stress, CKD, renal, antioxidant
   • Renal oxidant stress is a key factor in CKD progression. Tubular cells are highly metabolically active with high ROS exposure. Antioxidant supplementation is an important consideration.

2. Lawson JS, Sheridan A, Sherlock T, Elliott J, Sherck MJ, Mayeux M Renal accumulation of prooxidant mineral elements and CKD in domestic cats. Sci Rep. 2020. PMC: PMC7035273 | DOI: 10.1038/s41598-020-59876-6

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: prooxidant minerals, kidney, CKD, copper, zinc
   • Cat kidneys have significantly lower antioxidant minerals (Cu, Zn) vs dogs. Pro-oxidant renal environment from diet/genetics may contribute to high feline CKD prevalence.

3. Keegan RF, Webb CB Oxidative stress and neutrophil function in cats with chronic renal failure. J Vet Intern Med. 2010. PMID: 20384951

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: oxidative stress, GSH, GSSG, CRF, antioxidant capacity
   • CRF cats had higher GSH:GSSG ratio and lower antioxidant capacity — activation of antioxidant defenses but reduced overall capacity. First study of oxidative stress in feline CRF.

4. Chen XL, Fan JY, Quimby J Evaluation of oxidative stress in dogs and cats with chronic kidney disease. J Vet Intern Med. 2024. PMID: 39474931

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: oxidative stress, CKD, early stage, biomarkers
   • Oxidative stress peaks in early CKD in cats — therapeutic window for antioxidant intervention exists before disease progression.

5. Abreu CB, Lopes PA, Freitas M, Santos JL, et al. Efficacy of free glutathione and niosomal glutathione in the treatment of acetaminophen-induced hepatotoxicity in cats. Int J Pharm. 2015. PMC: PMC4629586

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: glutathione, niosomal GSH, acetaminophen, hepatotoxicity
   • Free GSH (200mg/kg) and niosomal GSH (14mg/kg) both effective against APAP hepatotoxicity in cats. Niosomal form shows targeted liver delivery.

6. Savides MC, Oehme FW, Nash SL, Leipold HW Acetylcysteine for treatment of acetaminophen toxicosis in the cat. J Am Vet Med Assoc. 1980. PMID: 7400022

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: NAC, acetaminophen, toxicosis, GSH replenishment
   • Established NAC as treatment of choice for feline acetaminophen toxicosis. NAC provides cysteine for GSH biosynthesis and directly inactivates NAPQI.

7. Antognoni MT, Siepi D, Porciello F, Rueca F, Fruganti G Antioxidant defence and oxidative stress markers in cats with hypertrophic cardiomyopathy. BMC Vet Res. 2020. PMC: PMC6990494

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: oxidative stress, HCM, SOD, catalase, antioxidant
   • SOD and catalase activities differ in HCM cats. Catalase lower in asymptomatic stage. Suggests beneficial effect of antioxidants on HCM progression.

8. Ma Q Role of Nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013. PMID: 23294312 | PMC: PMC4680839

   • Type: review | Species: mixed | Feline-specific: No | Tags: Nrf2, Keap1, ARE, antioxidant defense, review
   • Comprehensive review of Nrf2/Keap1/ARE pathway. Nrf2 controls expression of antioxidant response element-dependent genes including SOD, CAT, NQO1, GSH synthesis genes.

9. Kubo E, Chhunchha B, Singh P, Sasaki H, Singh DP Sulforaphane reactivates cellular antioxidant defense by inducing Nrf2/ARE/Prdx6 activity during aging and oxidative stress. Sci Rep. 2017. PMID: 29074861 | DOI: 10.1038/s41598-017-14520-8

   • Type: mechanistic | Species: mixed | Feline-specific: No | Tags: sulforaphane, Nrf2, Prdx6, aging, antioxidant
   • SFN augments Nrf2-dependent antioxidant expression (Prdx6, catalase, GSTπ) in dose-dependent fashion. Halts Nrf2 dysregulation during aging.

---

N06 — System 4: Cellular Senescence & Tissue Renewal (Essentially Unstudied in Cats)

Citations: 6 | Feline-specific: 2 | Translational: 4 Evidence types: clinical, review Species coverage: cat, mixed

1. Quimby JM, Maranon DG, Griessen JJ, Webb TL, Cianciolo RE, Laplante C Feline chronic kidney disease is associated with shortened telomeres and increased cellular senescence. Am J Physiol Renal Physiol. 2013. PMID: 23720342

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: senescence, telomere, CKD, SA-beta-gal, renal
   • CKD cats had significantly increased SA-β-gal staining in kidneys vs young cats. Shortened telomeres and increased senescence may represent novel therapeutic targets.

2. Quimby JM, et al. Renal Senescence, Telomere Shortening and Nitrosative Stress in Feline Chronic Kidney Disease. Vet Sci. 2021. PMC: PMC8703545

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: p16, senescence, telomere, iNOS, CKD
   • CKD cats had significantly increased p16 staining in renal cortex and corticomedullary junction vs adult/senior cats. p16 correlated with glomerulosclerosis, inflammation, fibrosis.

3. Kuyinu EL, et al. The potential for senotherapy as a novel approach to extend life quality in veterinary medicine. Front Vet Sci. 2024. PMID: 38812556 | PMC: PMC11133588

   • Type: review | Species: mixed | Feline-specific: No | Tags: senotherapy, senolytics, senomorphics, veterinary, CKD
   • Review of senotherapy for vet species. Feline CKD identified as naturally occurring model for senolytic testing. In vitro feline renal senescence established.

4. Kirkland JL, Tchkonia T Cellular senescence: a translational perspective. EBioMedicine. 2017. PMC: PMC9028163

   • Type: review | Species: mixed | Feline-specific: No | Tags: senescence, SASP, p16, p21, translational
   • Review of senescence biology: p16/p21 cell cycle arrest, SASP (IL-6, IL-8, MMP3/9), senolytic strategies. Framework for translational application.

5. Kim J, et al. Geroscience and aging interventions in dogs and cats: from mechanisms to clinical care. J Vet Sci. 2025. PMC: PMC12520856

   • Type: review | Species: mixed | Feline-specific: No | Tags: geroscience, aging, senescence, rapamycin, cats dogs
   • Geroscience targets mitochondrial dysfunction, inflammaging, and cellular senescence. Gaps remain in feline research. Senolytics identified as promising vet intervention.

6. Coppé JP, Desprez PY, Krtolica A, Campisi J The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010. PMID: 20078217

   • Type: review | Species: mixed | Feline-specific: No | Tags: SASP, senescence, IL-6, IL-8, MMP, tumor suppression
   • Definitive SASP review: IL-6, IL-8, MMP3/9, VEGF secretion by senescent cells. Paracrine damage to neighboring tissue. Foundation for senolytic rationale.

---

N07 — System 5: Genomic & Epigenetic Integrity (Early-Stage Feline Research)

Citations: 6 | Feline-specific: 5 | Translational: 1 Evidence types: RCT, clinical, mechanistic, review Species coverage: cat, mixed

1. Hoover EA, Mullins JI Feline leukemia virus infection and diseases. J Am Vet Med Assoc. 1991. PMID: 1666070

   • Type: review | Species: cat | Feline-specific: Yes | Tags: FeLV, retrovirus, oncogenic, immunosuppression
   • Comprehensive review of FeLV: oncogenic gammaretrovirus causing lymphoma, leukemia, myelosuppression, and immunodeficiency. Paradoxical cytoproliferative and cytosuppressive effects.

2. Fujino Y, Ohno K, Tsujimoto H Molecular pathogenesis of feline leukemia virus-induced malignancies: insertional mutagenesis. Vet J. 2008. PMID: 18313764

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: FeLV, insertional mutagenesis, c-myc, oncogene, lymphoma
   • FeLV causes malignancies via insertional mutagenesis at six loci (c-myc, flvi-1/2, fit-1, pim-1, flit-1). Provirus integrates near proto-oncogenes or disrupts tumor suppressors.

3. Raj K, Szladovits B, Haghani A, Zoller JA, Li CZ, Horvath S Epigenetic clock and methylation studies in cats. GeroScience. 2021. PMID: 34463900 | PMC: PMC8599556

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: epigenetic clock, DNA methylation, aging, CpG
   • Landmark feline epigenetic clock: three clocks (blood-only and dual human-cat). R=0.97 for cat blood. Uses conserved mammalian CpG sites. Also validated in cheetahs, tigers, lions.

4. Qi Y, et al. A cost-effective blood DNA methylation-based age estimation method in domestic cats, Tsushima leopard cats and Panthera species. Mol Ecol Resour. 2024. PMID: 38234258

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: DNA methylation, age estimation, machine learning, cost-effective
   • $3-7/sample targeted bisulfite method for feline age estimation. MAE 1.97 years in domestic cats (n=139). Applicable regardless of health condition.

5. Lu AT, Fei Z, Haghani A, et al. Universal DNA methylation age across mammalian tissues. Nat Aging. 2023. DOI: 10.1038/s43587-023-00462-6

   • Type: clinical | Species: mixed | Feline-specific: No | Tags: pan-mammalian, epigenetic clock, methylation, 185 species
   • Pan-mammalian epigenetic clock from 11,754 arrays across 185 species including cats. r>0.96 for age prediction across tissues.

6. Hoover EA, et al. Efficacy of an inactivated feline leukemia virus vaccine. AIDS Res Hum Retroviruses. 1996. PMID: 8882314

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: FeLV, vaccine, efficacy, protection
   • Inactivated FeLV vaccine from cloned subgroup A FeLV achieved 95% protection against persistent viremia. Durable immunity ≥1 year without booster.

---

N08 — System 6: Organ-System Reserve & Functional Capacity (Renal-Dominant, OA, Cognitive, Cardiac, Thyroid)

Citations: 8 | Feline-specific: 8 | Translational: 0 Evidence types: clinical, review Species coverage: cat

1. Lefort-Holguin M, Delsart A, Frezier M, Martin L, Otis C, Moreau M, et al. Osteoarthritis in cats: what we know, and mostly, what we don't know... yet. J Feline Med Surg. 2025. PMID: 40685570 | PMC: PMC12277680

   • Type: review | Species: cat | Feline-specific: Yes | Tags: osteoarthritis, prevalence, underdiagnosis, pain
   • OA prevalence 16-91% radiographically. 25.6% of cats (n=1772) had radiographic OA. 90% DJD in cats >12y. Massively underdiagnosed — cats do less rather than limp.

2. Enomoto M, Lascelles BDX, Gruen ME Development of a checklist for the detection of degenerative joint disease-associated pain in cats. J Feline Med Surg. 2020. PMC: PMC7736399

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: DJD, pain, checklist, detection
   • 39.1% of cats showed OA pain signs via checklist vs only 1% identified in medical records — 40× underdiagnosis gap.

3. Landsberg GM, Denenberg S, Araujo JA Cognitive dysfunction in cats: a syndrome we used to dismiss as 'old age'. J Feline Med Surg. 2010. PMID: 20974401 | PMC: PMC11220932

   • Type: review | Species: cat | Feline-specific: Yes | Tags: cognitive dysfunction, FCD, aging, behavioral
   • 28% of cats 11-14y develop ≥1 CDS behavior; 50% of cats >15y. Includes disorientation, vocalization, house-soiling. Beta-amyloid and tau deposits parallel human AD.

4. Sordo L, Gunn-Moore DA Cognitive Dysfunction in Cats: Update on Neuropathological and Behavioural Changes Plus Clinical Management. Vet Rec. 2021. PMID: 34651755

   • Type: review | Species: cat | Feline-specific: Yes | Tags: cognitive dysfunction, neuropathology, beta-amyloid, management
   • FCD shares similarities with human AD. No feline cognitive-diet trial equivalent to canine MCT studies exists. Functional neuron decline by 6-7 years.

5. Kittleson MD, Côté E The Feline Cardiomyopathies: 2. Hypertrophic cardiomyopathy. J Feline Med Surg. 2021. PMID: 34693811 | PMC: PMC8642168

   • Type: review | Species: cat | Feline-specific: Yes | Tags: HCM, cardiomyopathy, MYBPC3, prevalence
   • HCM affects ~15% of cats, mostly subclinical. MYBPC3 mutations in Maine Coons (A31P) and Ragdolls (R820W). No treatment reverses or slows disease.

6. Freeman LM, Rush JE, Stern JA, Huggins GS, Maron MS Feline Hypertrophic Cardiomyopathy: A Spontaneous Large Animal Model of Human HCM. Curr Heart Fail Rep. 2017. PMC: PMC5574284

   • Type: review | Species: cat | Feline-specific: Yes | Tags: HCM, translational model, human, genetics
   • Feline HCM is genotypically and phenotypically similar to human HCM. Excellent natural translational model.

7. Kittleson MD, Côté E The Feline Cardiomyopathies: 3. Cardiomyopathies other than HCM. J Feline Med Surg. 2021. PMID: 34693805

   • Type: review | Species: cat | Feline-specific: Yes | Tags: DCM, taurine, cardiomyopathy, deficiency
   • Taurine deficiency caused majority of feline DCM pre-1987. Now rare due to commercial diet supplementation. DCM is reversible with taurine supplementation.

8. MacQuiddy B, Moreno JA, Quimby JM Survey of risk factors and frequency of clinical signs observed with feline cognitive dysfunction syndrome. J Feline Med Surg. 2024. PMID: 35536055 | PMC: PMC11104230

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: FCD, risk factors, survey, vocalization
   • n=615 cats surveyed; 13% FCD-positive. Most common sign: inappropriate vocalization (40%). Rural environment may be protective.

---

Tier C — BDC Subsystems

N09 — BDC: Mitochondrial Integrity (Feline)

Citations: 12 | Feline-specific: 9 | Translational: 3 Evidence types: RCT, clinical, mechanistic, review Species coverage: cat, mixed, rodent

1. Blanchard G, Paragon BM, Serouge J, et al. Dietary L-carnitine supplementation in obese cats alters carnitine metabolism and decreases ketosis during fasting and induced hepatic lipidosis. J Nutr. 2002. PMID: 11823579

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: L-carnitine, beta-oxidation, hepatic lipidosis, ketosis
   • L-carnitine supplementation in obese cats protected against fasting ketosis and altered carnitine metabolism during experimental hepatic lipidosis.

2. Ibrahim WH, et al. Effects of carnitine and taurine on fatty acid metabolism and lipid accumulation in the liver of cats during weight gain and weight loss. Am J Vet Res. 2003. PMID: 14596465

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: L-carnitine, taurine, fatty acid metabolism, hepatic lipidosis
   • Primary mechanism of feline hepatic lipidosis is decreased fatty acid oxidation. Carnitine increased n-3/n-6 PUFA in hepatic triglycerides and plasma ketone bodies.

3. Verbrugghe A, Bakovic M Peculiarities of one-carbon metabolism in the strict carnivorous cat and the role in feline hepatic lipidosis. Nutrients. 2013. PMID: 23877091 | PMC: PMC3739000

   • Type: review | Species: cat | Feline-specific: Yes | Tags: one-carbon metabolism, L-carnitine, SAMe, hepatic lipidosis, obligate carnivore
   • SAMe is essential precursor for L-carnitine synthesis. Cobalamin deficiency may impair propionate metabolism reducing free carnitine for mitochondrial beta-oxidation.

4. Pion PD, Kittleson MD, Rogers QR, Morris JG Myocardial failure in cats associated with low plasma taurine: a reversible cardiomyopathy. Science. 1987. PMID: 3616607

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: taurine, DCM, cardiac, reversible, mitochondrial
   • Landmark discovery: taurine deficiency causes reversible DCM in cats. Taurine is present in millimolar concentrations in myocardium; depletion linked to myocardial failure.

5. Hayes KC, Carey RE, Schmidt SY Taurine: an essential nutrient for the cat. Science. 1975. PMID: 641594

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: taurine, essential amino acid, retinal degeneration
   • Established taurine as essential nutrient for cats. Cats cannot synthesize adequate taurine from cysteine due to low CSA decarboxylase activity.

6. Pion PD, Kittleson MD, Thomas WP, et al. Response of cats with dilated cardiomyopathy to taurine supplementation. J Am Vet Med Assoc. 1992. PMID: 1500324

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: taurine, DCM, supplementation, cardiac recovery
   • 37 cats with DCM given taurine; 59% had marked improvement and survived >240 days. All survivors remained stable on taurine alone after medication withdrawal.

7. Wu G Amino acids in the nutrition, metabolism, and health of domestic cats. Amino Acids. 2021. PMID: 33770409

   • Type: review | Species: cat | Feline-specific: Yes | Tags: amino acids, taurine, obligate carnivore, metabolism
   • Comprehensive review: cats cannot synthesize citrulline and have very limited taurine synthesis from cysteine. All essential amino acids must be dietary.

8. Quagliariello L, et al. Docosahexaenoate-enriched fish oil and medium chain triglycerides shape the feline plasma lipidome and synergistically decrease circulating gut microbiome-derived putrefactive postbiotics. BMC Vet Res. 2020. PMID: 32163448

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: MCT, DHA, fish oil, lipidome, ketone bodies, synergistic
   • FO+MCT synergistically increased ketone body production in cats beyond MCT alone. Shaped feline plasma lipidome across multiple lipid classes.

9. Leray V, et al. Effects of dietary medium-chain triglycerides on plasma lipids and lipoprotein distribution and food aversion in cats. J Feline Med Surg. 2010. PMID: 20367051

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: MCT, lipid metabolism, metabolic flexibility
   • MCT inclusion in cat diets did not cause food refusal and had minimal adverse effects on lipid metabolism. MCTs may serve as functional food ingredient for cats.

10. Khairallah RJ, et al. Dietary omega-3 fatty acids alter cardiac mitochondrial phospholipid composition and delay Ca2+-induced permeability transition. J Mol Cell Cardiol. 2010. PMID: 19703463

• Type: mechanistic | Species: rodent | Feline-specific: No | Tags: EPA, DHA, cardiolipin, mitochondrial membrane, permeability transition
• EPA+DHA altered mitochondrial phospholipid and cardiolipin composition by reducing arachidonic acid and increasing DHA incorporation. Translational evidence for cardiolipin remodeling.

11. Stanley WC, Khairallah RJ, Dabkowski ER Update on lipids and mitochondrial function: impact of dietary n-3 polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care. 2012. PMID: 22234165 | PMC: PMC4067133

• Type: review | Species: mixed | Feline-specific: No | Tags: n-3 PUFA, DHA, mitochondrial function, cardiolipin
• DHA has profound effects on mitochondrial membrane phospholipid composition. Supplementation decreases propensity for cardiac mitochondrial permeability transition.

12. Beynen AC Coenzyme Q10 in petfood. Creature Companion. 2020.

• Type: review | Species: mixed | Feline-specific: No | Tags: CoQ10, petfood, mitochondrial ETC
• Review notes no controlled experiments with dogs or cats substantiating CoQ10 health claims. No indirect evidence from which feline benefits may be inferred. Gap identified.

---

N10 — BDC: Oxidative Defense & Redox Balance (Feline)

Citations: 11 | Feline-specific: 9 | Translational: 2 Evidence types: PK study, RCT, clinical, review Species coverage: cat, mixed

1. Kocatürk M, et al. Plasma and erythrocyte glutathione peroxidase activity, serum selenium concentration, and plasma total antioxidant capacity in cats with IRIS stages I-IV chronic kidney disease. J Vet Intern Med. 2016. PMC: PMC4895542

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: selenium, GPx, CKD, antioxidant capacity, IRIS staging
   • Measured Se-GPx, serum selenium, and total antioxidant capacity across IRIS CKD stages in cats. No significant Se difference vs controls, but antioxidant capacity context established.

2. Quevedo WC, et al. Pharmacokinetics of N-acetylcysteine after oral and intravenous administration to healthy cats. Am J Vet Res. 2013. PMID: 23363356

   • Type: PK study | Species: cat | Feline-specific: Yes | Tags: NAC, pharmacokinetics, glutathione, oral bioavailability
   • Feline NAC PK: t1/2 0.78h IV, 1.34h oral; 33% oral bioavailability. Faster clearance than humans. Oral doses at 100mg/kg may still achieve therapeutic concentrations for chronic disease.

3. Webb CB, Twedt DC, Fettman MJ, Mason G S-adenosylmethionine (SAMe) in a feline acetaminophen model of oxidative injury. J Feline Med Surg. 2003. PMID: 12670431

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: SAMe, glutathione, oxidative injury, Heinz bodies, hepatoprotective
   • SAMe protected against acetaminophen-induced Heinz body formation and PCV decline in cats. Hepatic GSH:GSSG ratio tended to increase with SAMe treatment.

4. Center SA, et al. The effects of S-adenosylmethionine on clinical pathology and redox potential in the red blood cell, liver, and bile of clinically normal cats. J Vet Intern Med. 2005. PMID: 15954543

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: SAMe, redox potential, hepatic glutathione, RBC resilience, chronic dosing
   • 113-day chronic SAMe study in 15 healthy cats: improved RBC markers, hepatic redox status, augmented RBC osmotic resilience, and improved hepatic histology.

5. Chew BP, et al. Astaxanthin stimulates cell-mediated and humoral immune responses in cats. Vet Immunol Immunopathol. 2011. PMID: 21930306

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: astaxanthin, immune response, NK cell, IgG, IgM, antioxidant
   • Dose-related increase in plasma astaxanthin over 12 weeks. Enhanced DTH, PBMC proliferation, NK cytotoxicity, and increased IgG/IgM concentrations.

6. Park JS, et al. Astaxanthin uptake in domestic dogs and cats. Nutr Metab (Lond). 2010. PMC: PMC2898833

   • Type: PK study | Species: cat | Feline-specific: Yes | Tags: astaxanthin, uptake, HDL, mitochondrial localization, leukocytes
   • Astaxanthin in blood predominantly in HDL in cats. 40-50% of leukocyte astaxanthin localized to mitochondria. Maximal uptake by day 6, dose-related.

7. Jewell DE, et al. Effect of increasing dietary antioxidants on concentrations of vitamin E and total alkenals in serum of dogs and cats. Am J Vet Res. 2000. PMID: 19757574

   • Type: clinical | Species: mixed | Feline-specific: No | Tags: vitamin E, lipid peroxidation, alkenals, antioxidant blend
   • Threshold for significant serum alkenal reduction was 540 IU vitamin E/kg food in cats. Normal cats experience measurable oxidative damage reduced by dietary antioxidants.

8. Yu S, Bhatt R Vitamin E supplementation fails to impact measures of oxidative stress or the anaemia of feline chronic kidney disease: a randomised, double-blinded placebo control study. J Small Anim Pract. 2017. PMC: PMC5645861

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: vitamin E, CKD, oxidative stress, anemia, negative result
   • RCT: 30 IU vitamin E daily for 3 months did not significantly change oxidative stress markers or PCV in cats with CKD. Negative result for vitamin E monotherapy in feline CKD.

9. Christopher MM Erythrocyte pathology and mechanisms of Heinz body-mediated hemolysis in cats. Vet Clin Pathol. 1989. PMID: 2238384

   • Type: review | Species: cat | Feline-specific: Yes | Tags: Heinz bodies, feline hemoglobin, oxidative vulnerability, sulfhydryl groups
   • Feline hemoglobin has 8 reactive sulfhydryl groups (most of any mammal), making cat RBCs uniquely susceptible to oxidative damage. Up to 5-10% Heinz bodies normal in healthy cats.

10. Heaton PR, et al. Effect of dietary antioxidants on free radical damage in dogs and cats. J Nutr. 2024. PMID: 38828917

• Type: clinical | Species: mixed | Feline-specific: No | Tags: antioxidant blend, free radical damage, vitamin E, vitamin C, beta-carotene
• Antioxidant-enriched kibble (vitamin E, C, beta-carotene) enhanced cell protection and improved antioxidant status in both dogs and cats.

11. Machiels BM, et al. Quantification of plasma reduced glutathione, oxidized glutathione and plasma total glutathione in healthy cats. Vet Clin Pathol. 2024. PMC: PMC10832686

• Type: clinical | Species: cat | Feline-specific: Yes | Tags: glutathione, GSH, GSSG, redox balance, reference ranges
• Established feline plasma GSH reference ranges. Provides baseline for evaluating glutathione-based interventions in cats.

---

N11 — BDC: Inflammaging & Immune Calibration (Feline)

Citations: 10 | Feline-specific: 5 | Translational: 5 Evidence types: RCT, clinical, review Species coverage: cat, mixed

1. Harris DL, et al. Omega-3 fatty acids mitigate inflammation in felines with chronic kidney disease. FASEB J. 2012.

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: EPA, DHA, inflammation, CKD, SPM precursors
   • 63 client-owned cats with stage 2-3 CKD. Adequate DHA status decreased inflammation. Higher DHA intakes protected against malnutrition-inflammation syndrome as indicated by BCS and serum albumin.

2. Kobayashi S, et al. Renoprotective effects of docosahexaenoic acid in cats with early chronic kidney disease due to polycystic kidney disease: a pilot study. J Feline Med Surg. 2022. PMID: 36383208

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: DHA, renoprotective, CKD, PKD, SDMA, UPC
   • DHA-enriched fish oil for 28 days significantly decreased AA and increased DHA:AA ratio in CKD cats. Improved SDMA, UPC and urinary NAG index, suggesting renoprotective effects.

3. Fritsch DA, et al. Therapeutic effect of EPA/DHA supplementation in neoplastic and non-neoplastic companion animal diseases: a systematic review. Front Vet Sci. 2021. PMC: PMC8193331

   • Type: review | Species: mixed | Feline-specific: No | Tags: EPA, DHA, systematic review, companion animals, anti-inflammatory
   • Systematic review of EPA/DHA supplementation across companion animal diseases. Supports anti-inflammatory mechanisms via SPM precursor provision.

4. Serhan CN, Levy BD Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest. 2018. PMID: 29757195

   • Type: review | Species: mixed | Feline-specific: No | Tags: resolvins, SPM, pro-resolving mediators, EPA, DHA
   • Landmark review: SPMs (resolvins, protectins, maresins) from EPA/DHA actively resolve inflammation. 100-1000x more potent than NSAIDs. Defines resolution biology.

5. Kanakupt K, et al. Effects of short-chain fructooligosaccharides and galactooligosaccharides on nutrient digestibility, fecal fermentative metabolite concentrations, and large bowel microbial ecology of healthy adult cats. J Anim Sci. 2011. PMID: 21216981

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: FOS, GOS, prebiotics, butyrate, SCFA, Bifidobacterium, gut-immune
   • scFOS+GOS in cats increased Bifidobacterium, butyrate, valerate, total SCFAs, and decreased fecal pH. Direct evidence for prebiotic-driven SCFA production in obligate carnivores.

6. Wernimont SM, et al. The effects of nutrition on the gastrointestinal microbiome of cats and dogs: impact on health and disease. Front Microbiol. 2020. PMC: PMC7329990

   • Type: review | Species: mixed | Feline-specific: No | Tags: gut microbiome, nutrition, cats, dogs, immune modulation
   • Comprehensive review: GI microbiota contributes to defense against pathogens, nutrient digestion, barrier function, and immune regulation in cats and dogs.

7. Garcia-Mazcorro JF, et al. Effect of a multistrain probiotic on feline gut health through the fecal microbiota and its metabolite SCFAs. Microorganisms. 2023. PMC: PMC9962843

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: probiotic, feline, gut health, SCFA, microbiota
   • Multistrain probiotic modulated feline fecal microbiota and SCFA profiles. Supports gut-immune axis modulation in cats.

8. Gal A, et al. Efficacy of probiotic, prebiotic, synbiotic and postbiotic supplementation on gastrointestinal health in cats: systematic review and meta-analysis. J Feline Med Surg. 2025. PMC: PMC12000713

   • Type: review | Species: cat | Feline-specific: Yes | Tags: prebiotics, probiotics, systematic review, butyrate, cats
   • Systematic review: biotic supplementation increased butyric and propionic acid in 3/5 trials. Butyric acid increased in all 3 probiotic studies. FOS and GOS most recognized prebiotics.

9. Pilla R, Suchodolski JS The gut microbiome of dogs and cats, and the influence of diet. Vet Clin North Am Small Anim Pract. 2021.

   • Type: review | Species: mixed | Feline-specific: No | Tags: gut microbiome, diet, cats, dogs, SCFA, butyrate
   • Diet significantly shapes feline and canine gut microbiome. SCFA production (especially butyrate) is critical energy source for colonocytes with anti-inflammatory effects.

10. Wernimont SM, et al. Microbiota and probiotics in canine and feline welfare. Anaerobe. 2020. PMID: 25863311 | PMC: PMC7111060

• Type: review | Species: mixed | Feline-specific: No | Tags: microbiota, probiotics, welfare, cats, dogs, immune
• Beneficial flora produce SCFAs and bacteriocins that enhance epithelial barrier function and modulate immune response in cats and dogs.

---

N12 — BDC: Nutrient Sensing & Autophagy (Feline)

Citations: 8 | Feline-specific: 2 | Translational: 6 Evidence types: RCT, clinical, mechanistic, review Species coverage: cat, mixed

1. Nguyen P, et al. Delayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trial. J Am Vet Med Assoc. 2023. PMID: 37495229 | PMC: PMC10979416

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: rapamycin, mTOR, HCM, cardiac hypertrophy, feline
   • RAPACAT trial: once-weekly low-dose rapamycin (0.3mg/kg) significantly altered maximum wall thickness over 6 months in cats with subclinical HCM. First mTOR pathway inhibition trial in cats.

2. Khor S, et al. Multi-omic, histopathologic, and clinicopathologic effects of once-weekly oral rapamycin in a naturally occurring feline model of hypertrophic cardiomyopathy: a pilot study. Animals. 2023.

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: rapamycin, mTOR, multi-omic, HCM, feline model
   • Multi-omic pilot study of rapamycin in feline HCM. Cats develop spontaneous age-related HCM without genetic engineering, paralleling human cardiac aging via mTOR-driven hyperfunction.

3. Eisenberg T, et al. Induction of autophagy by spermidine promotes longevity. Nat Cell Biol. 2009. PMID: 19801973

   • Type: mechanistic | Species: mixed | Feline-specific: No | Tags: spermidine, autophagy, longevity, histone acetylation
   • Landmark study: spermidine induces autophagy and extends lifespan in yeast, nematodes, and flies. Genetic inactivation of autophagy genes abolishes lifespan extension.

4. Madeo F, et al. Spermidine: a novel autophagy inducer and longevity elixir. Autophagy. 2010. PMID: 20110777

   • Type: review | Species: mixed | Feline-specific: No | Tags: spermidine, autophagy, anti-aging, polyamine
   • Review: spermidine prolongs lifespan across multiple model organisms, reduces age-related oxidative protein damage in mice. May act as universal anti-aging compound.

5. Hofer SJ, et al. Mechanisms of spermidine-induced autophagy and geroprotection. Nat Aging. 2022. PMID: 37118547

   • Type: review | Species: mixed | Feline-specific: No | Tags: spermidine, autophagy, geroprotection, EP300, mechanisms
   • Comprehensive review: spermidine inhibits EP300 acetyltransferase, inducing autophagy. Modulates mitochondrial function, inflammation, and proteostasis. No veterinary studies cited.

6. Bozek K, et al. mTOR Complex 1 content and regulation is adapted to animal longevity. Int J Mol Sci. 2022. PMID: 35955882

   • Type: mechanistic | Species: mixed | Feline-specific: No | Tags: mTORC1, longevity, aging, species comparison
   • Decreased mTORC1 content and activity are key traits for animal longevity. Constitutive mTORC1 activity is a hallmark of aging and age-related diseases.

7. Campigotto G, et al. Nutritional needs and health outcomes of ageing cats and dogs: is it time for updated nutrient guidelines?. J Nutr Sci. 2024. PMC: PMC11188961

   • Type: review | Species: mixed | Feline-specific: No | Tags: aging, cats, dogs, nutrition, protein requirements
   • Cats require 2-3x more protein than dogs, increasing further in old age. Limited metabolic flexibility means hepatic catabolic enzymes remain set at high levels regardless of intake.

8. Valenzuela PL, et al. The protein paradox, carnivore diet and hypertrophy versus longevity. Ageing Res Rev. 2025. PMID: 40094942

   • Type: review | Species: mixed | Feline-specific: No | Tags: protein paradox, mTOR, carnivore diet, longevity, aging
   • High protein/amino acid intake activates mTORC1, opposing longevity. CR, PR, and methionine restriction suppress mTOR. Obligate carnivores cannot employ these strategies.

---

N13 — BDC: Proteostasis & ECM Maintenance (Feline)

Citations: 8 | Feline-specific: 5 | Translational: 3 Evidence types: RCT, mechanistic, review Species coverage: cat, mixed

1. Barbeau-Grégoire M, et al. A 2022 systematic review and meta-analysis of enriched therapeutic diets and nutraceuticals in canine and feline osteoarthritis. Int J Mol Sci. 2022. PMID: 36142319 | PMC: PMC9499673

   • Type: review | Species: mixed | Feline-specific: No | Tags: OA, nutraceuticals, glucosamine, chondroitin, omega-3, systematic review
   • Meta-analysis: omega-3 diets showed analgesic efficacy in OA. Glucosamine-chondroitin showed 'very marked non-effect.' Recommended against for pain management in canine/feline OA.

2. Vandeweerd JM, et al. Comparison of meloxicam and a glucosamine-chondroitin supplement in management of feline osteoarthritis: a double-blind randomised placebo-controlled prospective trial. Vet J. 2012. PMID: 24146058

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: glucosamine, chondroitin, meloxicam, OA, feline
   • Meloxicam significantly improved mobility in OA cats. Glucosamine-chondroitin supplement did not show equivalent benefits vs placebo in feline OA.

3. Gruen ME, et al. Evaluation of a nutritional supplement for the alleviation of pain associated with feline degenerative joint disease. J Feline Med Surg. 2022. PMID: 34719996

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: glucosamine, chondroitin, DJD, pain, negative result
   • Double-blind placebo-controlled trial: glucosamine/chondroitin (Dasuquin) did not show pain-relieving effects vs placebo in 59 cats with DJD.

4. Kim YJ, et al. Chondroitin sulfate alleviated lipopolysaccharide-induced arthritis in feline and canine articular chondrocytes through regulation of neurotrophic signaling pathways and apoptosis. BMC Vet Res. 2024. PMID: 39603024

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: chondroitin sulfate, articular chondrocytes, feline, in vitro, neurotrophic
   • CS treatment (800 µg/mL) enhanced feline chondrocyte viability and reduced oxidative stress in vitro. Mechanistic support despite negative clinical trial results.

5. Guarcello R, et al. Undenatured type II collagen (UC-II) in joint health and disease: a review on the current knowledge of companion animals. Animals. 2020. PMID: 32316397 | PMC: PMC7222752

   • Type: review | Species: mixed | Feline-specific: No | Tags: UC-II, collagen, oral tolerance, joint health, companion animals
   • UC-II exerts benefits via oral tolerance (GALT/Treg modulation). May be more effective than glucosamine/chondroitin at smaller dosages. Limited feline-specific efficacy data.

6. Verbrugghe A, Bakovic M Peculiarities of one-carbon metabolism in the strict carnivorous cat and the role in feline hepatic lipidosis. Nutrients. 2013. PMID: 23877091 | PMC: PMC3739000

   • Type: review | Species: cat | Feline-specific: Yes | Tags: one-carbon metabolism, SAMe, methionine, protein metabolism, obligate carnivore
   • Methionine is most limiting amino acid in feline diets. SAMe is universal methyl donor. Cats maintain consistently high protein oxidation and gluconeogenesis rates. Cross-ref N09.

7. Wu G Amino acids in the nutrition, metabolism, and health of domestic cats. Amino Acids. 2021. PMID: 33770409

   • Type: review | Species: cat | Feline-specific: Yes | Tags: amino acids, protein demand, coat, taurine, obligate carnivore
   • Cats have 2-3x higher protein requirements than dogs. Coat consumes 25-30% daily protein. All essential amino acids must be dietary. Cross-ref N09.

8. Neil KM, et al. The role of glucosamine and chondroitin sulfate in treatment for and prevention of osteoarthritis in animals. J Am Vet Med Assoc. 2005. PMID: 15825732

   • Type: review | Species: mixed | Feline-specific: No | Tags: glucosamine, chondroitin, OA, GAG, animals
   • Review of glucosamine/chondroitin in veterinary OA. Notes heterogeneous results. Glucosamine serves as UDP-GlcNAc precursor for GAG biosynthesis.

---

N14 — BDC: Genomic Stability & Cellular Resilience (Feline)

Citations: 8 | Feline-specific: 6 | Translational: 2 Evidence types: clinical, review Species coverage: cat, mixed

1. Verbrugghe A, Bakovic M Peculiarities of one-carbon metabolism in the strict carnivorous cat and the role in feline hepatic lipidosis. Nutrients. 2013. PMID: 23877091 | PMC: PMC3739000

   • Type: review | Species: cat | Feline-specific: Yes | Tags: one-carbon metabolism, SAMe, methylation, folate, B12
   • SAMe is universal methyl donor for all methylation reactions including DNA/histone methylation. Methionine→SAMe→methylation pathway critical in cats. Cross-ref N09, N13.

2. Raj K, Szladovits B, Haghani A, et al. Epigenetic clock and methylation studies in cats. GeroScience. 2021. PMID: 34463900

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: epigenetic clock, DNA methylation, aging, feline
   • Landmark feline epigenetic clock (R=0.97). DNA methylation age correlates with chronological age. Validates methylation as aging biomarker in cats. Cross-ref N07.

3. Qi Y, et al. A cost-effective blood DNA methylation-based age estimation method in domestic cats, leopard cats and Panthera species. Mol Ecol Resour. 2024. PMID: 38234258

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: DNA methylation, age estimation, epigenetic, feline
   • Blood-based DNA methylation age estimation across felid species. Extends epigenetic clock methodology for feline aging research. Cross-ref N07.

4. Quimby JM, et al. Feline chronic kidney disease is associated with shortened telomeres and increased cellular senescence. Am J Physiol Renal Physiol. 2013. PMID: 23720342

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: telomeres, senescence, p16, CKD, feline
   • CKD cats have shortened telomeres and p16-mediated senescence in renal tissue. Direct evidence linking genomic instability to feline aging pathology. Cross-ref N06.

5. Quimby JM, et al. Renal senescence, telomere shortening and nitrosative stress in feline chronic kidney disease. Vet Sci. 2021. PMC: PMC8703545

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: renal senescence, telomeres, nitrosative stress, CKD
   • Expanded evidence: renal senescence with telomere shortening and nitrosative stress markers in feline CKD. Cross-ref N06.

6. Fujino Y, Ohno K, Tsujimoto H Molecular pathogenesis of feline leukemia virus-induced malignancies: insertional mutagenesis. Vet J. 2008. PMID: 18313764

   • Type: review | Species: cat | Feline-specific: Yes | Tags: FeLV, insertional mutagenesis, genomic instability, retrovirus
   • FeLV insertional mutagenesis is best-characterized model of retroviral genomic disruption in cats. Cross-ref N07.

7. Lu AT, Fei Z, Haghani A, et al. Universal DNA methylation age across mammalian tissues. Nat Aging. 2023. DOI: 10.1038/s43587-023-00462-6

   • Type: clinical | Species: mixed | Feline-specific: No | Tags: DNA methylation, mammalian aging, universal clock, epigenetic
   • Universal mammalian methylation clock includes feline data. Validates cross-species epigenetic aging framework. Cross-ref N07.

8. Kuyinu EL, et al. The potential for senotherapy as a novel approach to extend life quality in veterinary medicine. Front Vet Sci. 2024. PMID: 38812556

   • Type: review | Species: mixed | Feline-specific: No | Tags: senotherapy, senolytics, veterinary, aging
   • Reviews senolytic potential in veterinary medicine. Notes fisetin and quercetin as leading flavonoid senolytic candidates. Cross-ref N06, N37.

---

Tier D — Key Ingredients

N15 — Preformed EPA/DHA (Marine Omega-3s — Feline Backbone)

Citations: 8 | Feline-specific: 5 | Translational: 3 Evidence types: clinical, guideline, mechanistic, review Species coverage: cat, mixed

1. Rivers JPW, Sinclair AJ, Crawford MA Inability of the cat to desaturate essential fatty acids. Nature. 1975. PMID: 1196143

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: delta-6 desaturase, ALA, EPA, DHA, obligate carnivore
   • Landmark: no significant delta-6 desaturase activity in cats. ALA-to-EPA conversion functionally zero. Cats require preformed EPA/DHA from animal sources.

2. Bauer JE Fatty acid metabolism in domestic cats and cheetahs. Proc Nutr Soc. 1997.

   • Type: review | Species: cat | Feline-specific: Yes | Tags: fatty acid metabolism, delta-6 desaturase, obligate carnivore, EPA, DHA
   • Confirmed limited delta-6 desaturase in cats and cheetahs. Obligate carnivores rely on prey to provide preformed long-chain PUFAs.

3. Harris DL, et al. Omega-3 fatty acids mitigate inflammation in felines with chronic kidney disease. FASEB J. 2012.

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: EPA, DHA, CKD, inflammation
   • 63 cats with stage 2-3 CKD: adequate DHA decreased inflammation and protected against malnutrition-inflammation syndrome. Cross-ref N11.

4. Kobayashi S, et al. Renoprotective effects of docosahexaenoic acid in cats with early CKD due to PKD. J Feline Med Surg. 2022. PMID: 36383208

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: DHA, renoprotective, SDMA, UPC
   • DHA fish oil improved SDMA, UPC and urinary NAG in cats with early CKD. Cross-ref N01, N11.

5. Sparkes AH, et al. ISFM consensus guidelines on the diagnosis and management of feline CKD. J Feline Med Surg. 2016. PMC: PMC11148907

   • Type: guideline | Species: cat | Feline-specific: Yes | Tags: IRIS, CKD, omega-3, guidelines, renal diet
   • ISFM guidelines recommend omega-3 supplementation for CKD cats. Renal diets with highest omega-3 content associated with longer survival. Cross-ref N04.

6. Lopez HL, et al. The balance of n-6 and n-3 fatty acids in canine, feline, and equine nutrition: exploring sources and the significance of alpha-linolenic acid. J Anim Sci. 2024. PMID: 38776363 | PMC: PMC11161904

   • Type: review | Species: mixed | Feline-specific: No | Tags: ALA, EPA, DHA, n-3, n-6, balance, feline
   • Comprehensive review: ALA conversion to EPA/DHA virtually zero in cats due to low delta-6 desaturase. Shared enzymes create competitive relationship between n-6 and n-3 pathways.

7. Fritsch DA, et al. Therapeutic effect of EPA/DHA supplementation in neoplastic and non-neoplastic companion animal diseases. Front Vet Sci. 2021. PMC: PMC8193331

   • Type: review | Species: mixed | Feline-specific: No | Tags: EPA, DHA, systematic review
   • Systematic review of EPA/DHA across companion animal diseases. Cross-ref N11.

8. Serhan CN, Levy BD Resolvins in inflammation: emergence of the pro-resolving superfamily. J Clin Invest. 2018. PMID: 29757195

   • Type: review | Species: mixed | Feline-specific: No | Tags: resolvins, SPM, EPA, DHA
   • SPMs from EPA/DHA actively resolve inflammation. 100-1000x more potent than NSAIDs. Cross-ref N11.

---

N16 — Taurine (Essential Amino Acid in Cats)

Citations: 6 | Feline-specific: 4 | Translational: 2 Evidence types: clinical, mechanistic, review Species coverage: cat, human, mixed

1. Singh P, et al. Taurine deficiency as a driver of aging. Science. 2023. PMID: 37289866 | PMC: PMC10630957

   • Type: mechanistic | Species: mixed | Feline-specific: No | Tags: taurine, aging, hallmarks, senescence, telomere, mitochondrial, inflammaging
   • Landmark: taurine declines with age in mice, monkeys, humans. Supplementation extended lifespan in mice, healthspan in monkeys. Reduced senescence, telomerase deficiency, mitochondrial dysfunction, DNA damage, inflammaging.

2. Pion PD, et al. Myocardial failure in cats associated with low plasma taurine: a reversible cardiomyopathy. Science. 1987. PMID: 3616607

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: taurine, DCM, cardiac, reversible
   • Landmark: taurine deficiency causes reversible DCM in cats. Cross-ref N09.

3. Hayes KC, et al. Taurine: an essential nutrient for the cat. Science. 1975. PMID: 641594

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: taurine, essential, retinal degeneration
   • Established taurine essentiality in cats. Low CSA decarboxylase activity. Cross-ref N09.

4. Pion PD, et al. Response of cats with dilated cardiomyopathy to taurine supplementation. J Am Vet Med Assoc. 1992. PMID: 1500324

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: taurine, DCM, supplementation, recovery
   • 37 cats with DCM: 59% survived >240 days on taurine alone. Cross-ref N09.

5. Wu G Amino acids in the nutrition, metabolism, and health of domestic cats. Amino Acids. 2021. PMID: 33770409

   • Type: review | Species: cat | Feline-specific: Yes | Tags: taurine, amino acids, obligate carnivore
   • Cats cannot synthesize citrulline and have very limited taurine synthesis. Cross-ref N09.

6. Marcangeli V, et al. Experimental evidence against taurine deficiency as a driver of aging in humans. Aging Cell. 2025. PMC: PMC12507425

   • Type: clinical | Species: human | Feline-specific: No | Tags: taurine, aging, human, negative result, counterpoint
   • Counterpoint to Singh 2023: circulating taurine not associated with age, muscle mass, or mitochondrial function in humans. Human relevance uncertain, but feline essentiality remains unchallenged.

---

N17 — B-Vitamins (B2, B3, B6, B12, Folate — Feline)

Citations: 6 | Feline-specific: 5 | Translational: 1 Evidence types: clinical, review Species coverage: cat, mixed

1. Ruaux CG, et al. Metabolism of amino acids in cats with severe cobalamin deficiency. Am J Vet Res. 2001. PMID: 11763170

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: cobalamin, B12, methylmalonic acid, amino acid metabolism
   • Cobalamin-deficient cats had MMA 9607 vs 448 nmol/L in healthy cats. Disturbed methionine/cystathionine/cysteine metabolism confirms one-carbon pathway disruption.

2. Reed N, et al. Vitamin B12 in cats: nutrition, metabolism, and disease. Animals. 2023. PMID: 37174511 | PMC: PMC10177498

   • Type: review | Species: cat | Feline-specific: Yes | Tags: B12, cobalamin, obligate carnivore, methylmalonic acid, one-carbon
   • Comprehensive feline B12 review. Cats require dietary B12, t1/2 11-14 days. MMA is primary biomarker for tissue-level deficiency. GI disease leads to malabsorption.

3. Kempf J, et al. Effects of 6 weeks of parenteral cobalamin supplementation on clinical and biochemical variables in cats with GI disease. J Vet Intern Med. 2017. PMID: 28895200 | PMC: PMC5697208

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: B12, cobalamin, supplementation, GI disease, MMA
   • 20 hypocobalaminemic cats: parenteral B12 normalized MMA and decreased clinical disease activity score. B12 increased from 111 to 2332.5 pmol/L.

4. Verbrugghe A, Bakovic M Peculiarities of one-carbon metabolism in the strict carnivorous cat. Nutrients. 2013. PMID: 23877091 | PMC: PMC3739000

   • Type: review | Species: cat | Feline-specific: Yes | Tags: one-carbon metabolism, folate, B12, SAMe, methionine
   • One-carbon metabolism in cats: folate cycle, methionine cycle, transsulfuration. SAMe is universal methyl donor. Cross-ref N09, N13, N14.

5. Fyfe JC, et al. Cobalamin deficiency associated with methylmalonic acidemia in a cat. J Am Vet Med Assoc. 1992. PMID: 1351478

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: B12, cobalamin, methylmalonic acidemia, inherited
   • Case report: inherited cobalamin absorption defect in a cat with methylmalonic acidemia, lethargy, anorexia, failure to thrive. Demonstrates feline vulnerability to B12 deficiency.

6. Woreta TA, et al. B vitamins and one-carbon metabolism: implications in human health and disease. Nutrients. 2020.

   • Type: review | Species: mixed | Feline-specific: No | Tags: B-vitamins, one-carbon metabolism, methylation, DNA repair
   • Translational review: B2 as FAD cofactor, B3 as NAD+ precursor, B6 in transsulfuration, B12/folate in one-carbon metabolism. Foundation for feline BDC pathway mapping.

---

N18 — Glutathione 50mg (LPL-01 Active: HE) and Comparative GSH-Pathway Context (⊘ NAC, ⊘ SAMe)

Citations: 6 | Feline-specific: 6 | Translational: 0 Evidence types: PK study, RCT, clinical, review Species coverage: cat

Formulation status: Glutathione (50mg/sachet) is in Hollywood Elixir. ⊘ NAC and ⊘ SAMe are NOT in any LPL-01 product — documented here as comparative GSH-pathway context. Feline note: SAMe has strong evidence for feline liver disease (cholangitis, hepatic lipidosis); NAC is used for feline acetaminophen toxicity rescue; both are excluded by formulation scope.

Biological role:

• Glutathione 50mg (HE active): Primary non-enzymatic intracellular antioxidant; substrate for GPx/GST; tripeptide (γ-Glu-Cys-Gly) directly neutralizes ROS, conjugates electrophiles via Phase II GST pathway (functional in cats; compensates for UGT1A6 pseudogene). Hepatic, erythrocyte, and renal GSH pools are of particular relevance given feline hemoglobin's 8 reactive sulfhydryl groups and carnivore GSH-dependent detoxification burden.
• ⊘ NAC (comparative — NOT in LPL-01): Cysteine prodrug providing rate-limiting substrate for de novo GSH biosynthesis; direct NAPQI scavenging in acetaminophen toxicity. Feline oral bioavailability 33%, t½ ~1.34h — shorter than humans. Used clinically for acetaminophen rescue in cats; NOT in LPL-01.
• ⊘ SAMe (comparative — NOT in LPL-01): Universal methyl donor; transsulfuration pathway substrate feeding GSH biosynthesis; feline hepatoprotective in acetaminophen, cholangitis, and hepatic lipidosis models. NOT in LPL-01.

Claims:

• Glutathione 50mg (HE active): direct ROS neutralization; GSH/GSSG redox balance; Phase II GST conjugation substrate; hepatic and erythrocyte GSH pool support in cats [B]
• ⊘ NAC: cysteine-donor GSH precursor; feline acetaminophen rescue standard of care; NOT in LPL-01 [B — comparative only]
• ⊘ SAMe: methyl-donor upstream of transsulfuration/GSH synthesis; feline hepatoprotective in acetaminophen/HL/cholangitis; NOT in LPL-01 [B — comparative only]

Cross-references: N05 (oxidative stress), N10 (oxidative defense), N02 (feline PK/UGT1A6), N32 (glucuronidation cost).

1. Webb CB, et al. S-adenosylmethionine (SAMe) in a feline acetaminophen model of oxidative injury. J Feline Med Surg. 2003. PMID: 12670431

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: SAMe, glutathione, oxidative injury, Heinz bodies
   • SAMe protected against acetaminophen-induced Heinz bodies and PCV decline. Cross-ref N10.

2. Center SA, et al. Effects of S-adenosylmethionine on clinical pathology and redox potential in clinically normal cats. J Vet Intern Med. 2005. PMID: 15954543

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: SAMe, redox, hepatic glutathione, chronic dosing
   • 113-day chronic SAMe in 15 healthy cats: improved RBC markers, hepatic redox, osmotic resilience. Cross-ref N10.

3. Quevedo WC, et al. Pharmacokinetics of NAC after oral and IV administration to healthy cats. Am J Vet Res. 2013. PMID: 23363356

   • Type: PK study | Species: cat | Feline-specific: Yes | Tags: NAC, pharmacokinetics, glutathione, oral bioavailability
   • Feline NAC PK: t1/2 1.34h oral, 33% bioavailability. Faster clearance than humans. Cross-ref N10.

4. Abreu CB, et al. Efficacy of free glutathione and niosomal glutathione in acetaminophen-induced hepatotoxicity in cats. Int J Pharm. 2015. PMC: PMC4629586

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: glutathione, niosomal, acetaminophen, hepatotoxicity
   • Both free and niosomal glutathione showed hepatoprotective effects in acetaminophen-intoxicated cats. Cross-ref N05.

5. Machiels BM, et al. Quantification of plasma reduced glutathione, oxidized glutathione and total glutathione in healthy cats. Vet Clin Pathol. 2024. PMC: PMC10832686

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: glutathione, GSH, GSSG, reference ranges
   • Established feline plasma GSH reference ranges. Cross-ref N10.

6. Court MH Feline drug metabolism and disposition: pharmacokinetic evidence for species differences. Vet Clin North Am Small Anim Pract. 2013. PMID: 23890237

   • Type: review | Species: cat | Feline-specific: Yes | Tags: glucuronidation, sulfation, GSH conjugation, phase II, feline PK
   • GSH conjugation carries proportionally larger detoxification burden in cats due to UGT1A6 pseudogene. SAMe/GSH pathway elevated significance. Cross-ref N02.

---

N19 — CoQ10 (Ubiquinone/Ubiquinol — Feline)

Citations: 4 | Feline-specific: 1 | Translational: 3 Evidence types: clinical, mechanistic, review Species coverage: cat, mixed, rodent

1. Beynen AC Coenzyme Q10 in petfood. Creature Companion. 2020.

   • Type: review | Species: mixed | Feline-specific: No | Tags: CoQ10, petfood, ETC
   • No controlled experiments with dogs or cats substantiate CoQ10 health claims. No indirect evidence for feline benefits. Cross-ref N09.

2. Khairallah RJ, et al. Dietary omega-3 fatty acids alter cardiac mitochondrial phospholipid composition. J Mol Cell Cardiol. 2010. PMID: 19703463

   • Type: mechanistic | Species: rodent | Feline-specific: No | Tags: mitochondrial, ETC, membrane
   • Mitochondrial ETC context. Cross-ref N09.

3. Stanley WC, et al. Update on lipids and mitochondrial function: impact of dietary n-3 PUFAs. Curr Opin Clin Nutr Metab Care. 2012. PMC: PMC4067133

   • Type: review | Species: mixed | Feline-specific: No | Tags: mitochondrial function, CoQ10, n-3 PUFA
   • Mitochondrial function review with CoQ10/ETC context. Cross-ref N09.

4. Antognoni MT, et al. Antioxidant defence and oxidative stress markers in cats with hypertrophic cardiomyopathy. BMC Vet Res. 2020. PMC: PMC6990494

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: HCM, oxidative stress, antioxidant, cardiac
   • Oxidative stress markers in feline HCM. Context for CoQ10 theoretical cardiac benefit. Cross-ref N05.

---

N20 — Astaxanthin (Feline)

Citations: 2 | Feline-specific: 2 | Translational: 0 Evidence types: PK study, RCT Species coverage: cat

1. Chew BP, et al. Astaxanthin stimulates cell-mediated and humoral immune responses in cats. Vet Immunol Immunopathol. 2011. PMID: 21930306

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: astaxanthin, immune, antioxidant
   • 12-week dose-response RCT in cats. Enhanced DTH, NK cell activity, IgG/IgM. Cross-ref N10.

2. Park JS, et al. Astaxanthin uptake in domestic dogs and cats. Nutr Metab (Lond). 2010. PMC: PMC2898833

   • Type: PK study | Species: cat | Feline-specific: Yes | Tags: astaxanthin, uptake, HDL, mitochondrial
   • 40-50% of leukocyte astaxanthin localizes to mitochondria in cats. Maximal uptake by day 6. Cross-ref N10.

---

N21 — Vitamins C & E (Feline)

Citations: 4 | Feline-specific: 2 | Translational: 2 Evidence types: RCT, clinical, review Species coverage: cat, mixed

1. Jewell DE, et al. Effect of increasing dietary antioxidants on vitamin E and alkenals in serum of dogs and cats. Am J Vet Res. 2000. PMID: 19757574

   • Type: clinical | Species: mixed | Feline-specific: No | Tags: vitamin E, lipid peroxidation, alkenals
   • Threshold for alkenal reduction: 540 IU vitamin E/kg in cats. Cross-ref N10.

2. Yu S, Bhatt R Vitamin E supplementation fails to impact oxidative stress or anaemia of feline CKD. J Small Anim Pract. 2017. PMC: PMC5645861

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: vitamin E, CKD, negative result
   • Negative RCT: 30 IU vitamin E daily x3 months did not change oxidative stress or PCV in CKD cats. Cross-ref N10.

3. Heaton PR, et al. Effect of dietary antioxidants on free radical damage in dogs and cats. J Nutr. 2024. PMID: 38828917

   • Type: clinical | Species: mixed | Feline-specific: No | Tags: antioxidant blend, vitamin E, vitamin C, beta-carotene
   • Antioxidant blend (E+C+beta-carotene) enhanced cell protection in cats. Cross-ref N10.

4. MacDonald ML, Rogers QR, Morris JG Nutrition of the domestic cat, a mammalian carnivore. Annu Rev Nutr. 1984. PMID: 6380542

   • Type: review | Species: cat | Feline-specific: Yes | Tags: vitamin C, endogenous synthesis, obligate carnivore
   • Cats synthesize vitamin C endogenously unlike humans. Supplementation benefit uncertain. Cross-ref N02.

---

N22 — Zinc (chelated) 1.5mg (LPL-01 Active: PG) and Comparative Metalloenzyme Context (⊘ Selenium, ⊘ Copper, ⊘ Manganese)

Citations: 4 | Feline-specific: 4 | Translational: 0 Evidence types: clinical Species coverage: cat

Formulation status: Zinc (chelated, 1.5mg/sachet) is in Pet Gala. ⊘ Selenium, ⊘ Copper, and ⊘ Manganese are NOT in any LPL-01 product. Feline note: selenoprotein P is essential for feline retinal maintenance; dietary selenium sufficiency is assumed on commercial diets. The GPx selenoprotein pathway is addressed in LPL-01 via Zinc/SOD (PG) and Glutathione (HE) as complementary mechanisms.

Biological role:

• Zinc (chelated) 1.5mg (PG active): Structural cofactor for Cu/Zn-SOD (SOD1) — the primary cytosolic superoxide dismutase; essential for zinc-finger transcription factors, DNA repair enzymes (e.g., PARP, ZnF nucleases), and metallothionein-mediated oxidative buffering. Chelated form (amino-acid or glycinate) provides improved feline absorption vs. inorganic salts. Addresses feline renal Cu/Zn deficit documented by Lawson et al. (2020).
• ⊘ Selenium (comparative — NOT in LPL-01): Essential cofactor for the GPx selenoprotein family and selenoprotein P (retinal maintenance). Cats have narrower therapeutic window than dogs and regulate Se homeostasis via urinary excretion. Dietary sufficiency assumed on commercial diets.
• ⊘ Copper (comparative — NOT in LPL-01): Cu/Zn-SOD cofactor; ceruloplasmin/iron metabolism; excluded as standalone due to feline hepatic copper accumulation risk and absence from LPL-01 SKU.
• ⊘ Manganese (comparative — NOT in LPL-01): Mn-SOD (SOD2, mitochondrial) cofactor; arginase and glycosyltransferases. NOT in LPL-01.

Claims:

• Zinc (chelated) 1.5mg (PG active): Cu/Zn-SOD cofactor; DNA repair zinc-finger support; metallothionein induction; addresses documented feline renal Cu/Zn deficit [B]
• ⊘ Selenium: GPx/selenoprotein P cofactor; narrow feline therapeutic window; NOT in LPL-01 [B — comparative only]
• ⊘ Copper: SOD1 cofactor; standalone copper NOT in LPL-01 [C — comparative only]
• ⊘ Manganese: mitochondrial Mn-SOD cofactor; NOT in LPL-01 [C — comparative only]

Cross-references: N05 (oxidative stress), N10 (oxidative defense), N02 (feline Se tolerance), N14 (DNA repair/zinc fingers).

1. Kocatürk M, et al. Plasma and erythrocyte GPx activity, serum selenium, and total antioxidant capacity in cats with IRIS stages I-IV CKD. J Vet Intern Med. 2016. PMC: PMC4895542

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: selenium, GPx, CKD
   • Se-GPx and total antioxidant capacity measured across CKD stages in cats. Cross-ref N10.

2. Van Hoek I, et al. Selenium status in adult cats and dogs fed high levels of dietary inorganic and organic selenium. J Anim Physiol Anim Nutr. 2012. PMID: 22307479

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: selenium, organic, inorganic, cats
   • Selenium status characterized in cats at various dietary levels. Cross-ref N02.

3. Wedekind KJ, et al. Selenium balance in the adult cat in relation to intake of dietary sodium selenite and organically bound selenium. J Anim Physiol Anim Nutr. 2011. PMID: 21320178

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: selenium, balance, selenite, organic selenium
   • Selenium balance study in adult cats. Narrower therapeutic window than dogs. Cross-ref N02.

4. Lawson JS, et al. Renal accumulation of prooxidant mineral elements and CKD in domestic cats. Sci Rep. 2020. PMC: PMC7035273

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: copper, zinc, renal, CKD, prooxidant
   • Cat kidneys have lower Cu/Zn ratio than dogs. Prooxidant mineral accumulation in feline CKD. Cross-ref N05.

---

N23 — L-Carnitine (Feline)

Citations: 3 | Feline-specific: 3 | Translational: 0 Evidence types: RCT, clinical, review Species coverage: cat

1. Blanchard G, et al. Dietary L-carnitine supplementation in obese cats alters carnitine metabolism and decreases ketosis during fasting and induced hepatic lipidosis. J Nutr. 2002. PMID: 11823579

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: L-carnitine, hepatic lipidosis, beta-oxidation, ketosis
   • L-carnitine protected obese cats from fasting ketosis. Cross-ref N09.

2. Ibrahim WH, et al. Effects of carnitine and taurine on fatty acid metabolism in the liver of cats. Am J Vet Res. 2003. PMID: 14596465

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: L-carnitine, taurine, fatty acid oxidation
   • Primary mechanism of feline hepatic lipidosis is decreased fatty acid oxidation. Carnitine increased PUFA in hepatic triglycerides. Cross-ref N09.

3. Verbrugghe A, Bakovic M Peculiarities of one-carbon metabolism in the strict carnivorous cat. Nutrients. 2013. PMID: 23877091

   • Type: review | Species: cat | Feline-specific: Yes | Tags: L-carnitine, SAMe, beta-oxidation, obligate carnivore
   • SAMe essential for L-carnitine synthesis. Cobalamin deficiency impairs carnitine availability. Cross-ref N09, N17.

---

N24 — ⊘ MCTs (C8/C10) — NOT in LPL-01 Formulation — Comparative Feline Cognitive Geroscience Context

Citations: 3 | Feline-specific: 3 | Translational: 0 Evidence types: RCT, clinical, review Species coverage: cat

⊘ Formulation status: MCTs are NOT in any LPL-01 product. Feline note: MCTs are well-tolerated in cats; FCDS (Feline Cognitive Dysfunction Syndrome) is increasingly recognized in cats over age 10–11; ketone bodies provide alternative neuronal fuel. Not in current SKU.

Biological role (comparative — NOT in LPL-01): Medium-chain triglycerides (C8 caprylic, C10 capric) bypass carnitine-dependent β-oxidation, rapidly generating ketone bodies (β-hydroxybutyrate, acetoacetate) that cross the blood-brain barrier and serve as alternative neuronal fuel in states of impaired cerebral glucose metabolism — a defining feature of FCDS and canonical AD-like neuropathology in aged cats. MCT+fish oil synergy documented in feline plasma lipidome (Quagliariello et al. 2020). No MCT-based LPL-01 product at this time.

Claims:

• ⊘ MCT C8/C10: ketogenic neuronal fuel substrate; bypasses carnitine-dependent β-oxidation; well-tolerated in cats; FCDS-relevant mechanism; NOT in LPL-01 [C — comparative only]

Cross-references: N08 (cognitive organ reserve), N09 (mitochondrial integrity / β-oxidation), N15 (EPA/DHA synergy).

1. Quagliariello L, et al. DHA-enriched fish oil and MCT shape the feline plasma lipidome. BMC Vet Res. 2020. PMID: 32163448

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: MCT, DHA, lipidome, ketone bodies
   • FO+MCT synergistically increased ketone body production in cats. Cross-ref N09.

2. Leray V, et al. Effects of dietary MCTs on plasma lipids and lipoprotein distribution in cats. J Feline Med Surg. 2010. PMID: 20367051

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: MCT, lipid metabolism, cats
   • MCTs well-tolerated in cats with minimal adverse effects on lipid metabolism. Cross-ref N09.

3. Landsberg GM, et al. Cognitive dysfunction in cats: a syndrome we used to dismiss as old age. J Feline Med Surg. 2010. PMID: 20974401

   • Type: review | Species: cat | Feline-specific: Yes | Tags: cognitive dysfunction, FCD, aging, cats
   • Feline cognitive dysfunction is real but underdiagnosed. No validated feline MCT cognitive trial exists. Cross-ref N08.

---

N25 — ⊘ Sulforaphane — NOT in LPL-01 Formulation — Comparative Nrf2/Antioxidant Context

Citations: 4 | Feline-specific: 2 | Translational: 2 Evidence types: mechanistic, review Species coverage: cat, mixed

⊘ Formulation status: Sulforaphane is NOT in any LPL-01 product. Safe in cats at culinary doses; Nrf2 induction relevant given limited feline Phase II capacity. Not in current SKU.

Biological role (comparative — NOT in LPL-01): Sulforaphane is the prototypical dietary Nrf2 activator; modifies Keap1 cysteine residues, releasing Nrf2 for nuclear translocation and ARE-dependent transcription of Phase II enzymes (NQO1, HO-1, GCL, GST). Metabolized via GST (not UGT) — a feline-safe Phase II pathway. No feline efficacy trial exists. Not in LPL-01 SKU; Nrf2/ARE induction in current formulation is addressed indirectly via Glutathione, Astaxanthin, Resveratrol, and Quercetin (HE).

Claims:

• ⊘ Sulforaphane: Nrf2/Keap1/ARE master antioxidant pathway activator; GST-dependent metabolism is feline-compatible; no feline efficacy RCT; NOT in LPL-01 [C — comparative only]

Cross-references: N05 (Nrf2/oxidative defense), N10 (oxidative defense), N02 (feline Phase II).

1. Ma Q Role of Nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013. PMID: 23294312

   • Type: review | Species: mixed | Feline-specific: No | Tags: Nrf2, Keap1, oxidative stress, phase II enzymes
   • Nrf2 master regulator of antioxidant/detoxification genes. Foundation for SFN mechanism. Cross-ref N05.

2. Kubo E, et al. Sulforaphane reactivates cellular antioxidant defense by inducing Nrf2/ARE/Prdx6 during aging and oxidative stress. Sci Rep. 2017. PMID: 29074861

   • Type: mechanistic | Species: mixed | Feline-specific: No | Tags: sulforaphane, Nrf2, Prdx6, aging, antioxidant
   • SFN reactivates age-declined Nrf2/ARE/Prdx6 pathway. Dose-dependent Phase II enzyme induction. Cross-ref N05.

3. Christopher MM Erythrocyte pathology and mechanisms of Heinz body-mediated hemolysis in cats. Vet Clin Pathol. 1989. PMID: 2238384

   • Type: review | Species: cat | Feline-specific: Yes | Tags: Heinz bodies, oxidative vulnerability, isothiocyanate caution
   • Feline hemoglobin has 8 reactive sulfhydryl groups — context for caution with any electrophilic compound including isothiocyanates. Cross-ref N10.

4. Court MH Feline drug metabolism and disposition. Vet Clin North Am Small Anim Pract. 2013. PMID: 23890237

   • Type: review | Species: cat | Feline-specific: Yes | Tags: GST pathway, phase II, sulforaphane safety, glucuronidation
   • Sulforaphane metabolized via GST (not UGT) — feline-safe pathway. Court 2013 confirms GST is functional in cats. Cross-ref N02.

---

N26 — ⊘ Spermidine — NOT in LPL-01 Formulation — Comparative Autophagy Context

Citations: 4 | Feline-specific: 0 | Translational: 4 Evidence types: RCT_preclinical, mechanistic, review Species coverage: mixed, rodent, yeast/worm/fly

⊘ Formulation status: Spermidine is NOT in any LPL-01 product. Not in current SKU.

Biological role (comparative — NOT in LPL-01): Natural polyamine; induces autophagy via EP300 acetyltransferase inhibition (mTOR-independent); documented lifespan extension in yeast, nematodes, flies, mice; cardioprotective and mitophagy-inducing in rodent models. Polyamine levels decline with aging. Zero feline studies of any kind. Not in LPL-01 SKU; autophagy/proteostasis support in the current system is addressed via NAD+ precursor (NR, HE) and EPA/DHA resolvin-mediated inflammaging modulation (PG).

Claims:

• ⊘ Spermidine: EP300-inhibition → autophagy/mitophagy induction; rodent lifespan extension; zero feline data; NOT in LPL-01 [D — comparative only]

Cross-references: N12 (nutrient sensing/autophagy), N06 (cellular senescence), N38 (feline evidence gaps).

1. Eisenberg T, Knauer H, Schauer A, et al. Induction of autophagy by spermidine promotes longevity. Nat Cell Biol. 2009. PMID: 19855400

   • Type: mechanistic | Species: yeast/worm/fly | Feline-specific: No | Tags: spermidine, autophagy, lifespan, EP300
   • Landmark discovery: spermidine induces autophagy via EP300 acetyltransferase inhibition and extends lifespan across model organisms.

2. Madeo F, Eisenberg T, Büttner S, et al. Spermidine: a novel autophagy inducer and longevity elixir. Autophagy. 2010. PMID: 20110777

   • Type: review | Species: mixed | Feline-specific: No | Tags: spermidine, autophagy, geroprotection
   • Review of spermidine as mTOR-independent autophagy inducer. Polyamine levels decline with aging across species.

3. Hofer SJ, Simon AK, Bergmann M, et al. Mechanisms of spermidine-induced autophagy and geroprotection. Nat Aging. 2022. PMID: 37118547

   • Type: review | Species: mixed | Feline-specific: No | Tags: spermidine, autophagy, aging, mechanism
   • Comprehensive mechanistic review. EP300 inhibition, histone acetylation modulation, mitophagy induction. Age-related polyamine decline documented.

4. Eisenberg T, Abdellatif M, Schroeder S, et al. Cardioprotection and lifespan extension by the natural polyamine spermidine. Nat Med. 2016. PMID: 27869803

   • Type: RCT_preclinical | Species: rodent | Feline-specific: No | Tags: spermidine, cardiac, autophagy, mitophagy, lifespan
   • Oral spermidine extends mouse lifespan and exerts cardioprotection via enhanced autophagy and mitophagy. Failed in Atg5-knockout cardiomyocytes, confirming autophagy-dependent mechanism.

---

N27 — ⊘ Prebiotics / Fermentable Fiber — NOT in LPL-01 Formulation — Comparative Gut-Immune Context

Citations: 5 | Feline-specific: 3 | Translational: 2 Evidence types: RCT, review, systematic_review Species coverage: cat, cat/dog, dog/cat

⊘ Formulation status: Prebiotics/fiber are NOT in any LPL-01 product. Feline note: obligate carnivore GI physiology limits fiber fermentation relevance vs. canine, but SCFA-mediated immune regulation remains relevant. Not in current SKU.

Biological role (comparative — NOT in LPL-01): FOS, GOS, and other fermentable fibers are metabolized by colonic microbiota into short-chain fatty acids (butyrate, propionate, acetate). Butyrate is the primary energy source for colonocytes, strengthens tight-junction epithelial barrier, and modulates Treg differentiation and NF-κB activity. Feline microbiome differs from canine; scFOS+GOS shown to increase Bifidobacterium and butyrate in cats. Not in LPL-01 SKU; gut-immune/inflammaging axis in current formulation is addressed via EPA/DHA resolvins (PG), Beta-Glucans (HE), and Quercetin NLRP3 suppression (HE).

Claims:

• ⊘ Prebiotics/FOS/GOS: SCFA/butyrate production; epithelial barrier and Treg support; evidence mixed in obligate carnivore; NOT in LPL-01 [C — comparative only]

Cross-references: N04 (inflammaging/gut-immune), N11 (inflammaging BDC).

1. Kanakupt K, Vester Boler BM, Dunsford BR, Fahey GC Jr. Effects of short-chain fructooligosaccharides and galactooligosaccharides on fecal microbiota and SCFA concentrations in cats. J Anim Sci. 2011. PMID: 21521815

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: FOS, GOS, butyrate, SCFA, microbiome, Bifidobacterium
   • FOS+GOS supplementation increased Bifidobacterium, butyrate, total SCFA, and lowered fecal pH in cats. Cross-ref N11.

2. López Martí I, et al. Efficacy of probiotic, prebiotic, synbiotic and postbiotic supplementation on gastrointestinal health in cats: systematic review and meta-analysis. J Small Anim Pract. 2025. PMC: PMC12000713

   • Type: systematic_review | Species: cat | Feline-specific: Yes | Tags: prebiotics, probiotics, SCFA, butyrate, systematic_review
   • Systematic review of 121 cats across 8 trials. Acetic, propionic, and butyric acids increased in 3 of 6 studies. Clinical efficacy remains uncertain.

3. Wernimont SM, Radosevich J, Jackson MI, et al. The effects of nutrition on the gastrointestinal microbiome of cats and dogs: impact on health and disease. Front Microbiol. 2020. PMC: PMC7329990

   • Type: review | Species: cat/dog | Feline-specific: No | Tags: fiber, microbiome, SCFA, butyrate, colonocytes
   • Fiber inclusion improved stool quality, lowered pH, increased beneficial microbes. Butyrate is main energy source for colonocytes. Effects depend on baseline microbiome.

4. Pilla R, Suchodolski JS. The role of the canine gut microbiome and metabolome in health and gastrointestinal disease. Front Vet Sci. 2020. PMC: PMC6978862

   • Type: review | Species: dog/cat | Feline-specific: No | Tags: microbiome, SCFA, dysbiosis
   • Comprehensive review of gut microbiome in companion animals. Cats show more Firmicutes and Proteobacteria than dogs. Hindgut fermentation relevant despite carnivore status.

5. Garcia-Mazcorro JF, et al. Feline gut microbiome composition and function. Vet Sci. 2023.

   • Type: review | Species: cat | Feline-specific: Yes | Tags: microbiome, carnivore, fermentation
   • Feline microbiome distinct from canine. FOS supplementation at 4% increased bifidobacteria and decreased E. coli. Cross-ref N11.

---

N28 — ⊘ Boswellia Serrata — NOT in LPL-01 Formulation — Comparative 5-LOX Anti-Inflammatory Context

Citations: 3 | Feline-specific: 0 | Translational: 3 Evidence types: RCT, clinical_trial, review Species coverage: dog, human, human/rodent

⊘ Formulation status: Boswellia is NOT in any LPL-01 product. Not in current SKU.

Biological role (comparative — NOT in LPL-01): Boswellic acids (notably AKBA) inhibit 5-lipoxygenase (5-LOX) and human leukocyte elastase (HLE), suppressing leukotriene-driven inflammation; complementary to COX-targeted NSAIDs. Canine joint data supportive; no feline efficacy RCT; no feline PK/safety data. Not in LPL-01 SKU; anti-inflammatory and joint support in current formulation is addressed via EPA/DHA SPMs (PG), Quercetin (HE), MSM, HA, and Marine Collagen Peptides (PG).

Claims:

• ⊘ Boswellia / AKBA: 5-LOX and HLE inhibition; canine joint support evidence; no feline data; NOT in LPL-01 [D — comparative only]

Cross-references: N04 (inflammatory tone), N13 (proteostasis/ECM joint), N30 (joint substrates).

1. Reichling J, Schmökel H, Fitzi J, et al. Dietary support with Boswellia resin in canine inflammatory joint and spinal disease. Schweiz Arch Tierheilkd. 2004. PMID: 14994484

   • Type: clinical_trial | Species: dog | Feline-specific: No | Tags: boswellia, joint, anti-inflammatory, canine
   • Open multi-centre veterinary trial: 29 dogs with chronic joint/spinal disease. 71% showed overall efficacy after 2 weeks. Significant reduction in lameness, local pain, stiff gait after 6 weeks.

2. Siddiqui MZ. Boswellia serrata, a potential antiinflammatory agent: an overview. Indian J Pharm Sci. 2011. PMID: 22457547

   • Type: review | Species: human/rodent | Feline-specific: No | Tags: boswellia, AKBA, 5-LOX, HLE, anti-inflammatory
   • AKBA is most potent 5-LOX inhibitor among four boswellic acids. Inhibits both 5-lipoxygenase and human leukocyte elastase (HLE). No feline-specific studies referenced.

3. Sengupta K, Alluri KV, Satber AR, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. 2008. PMID: 18667054

   • Type: RCT | Species: human | Feline-specific: No | Tags: 5-Loxin, AKBA, 5-LOX, osteoarthritis
   • Human RCT: 5-Loxin (30% AKBA) showed clinically significant improvements in pain and function within 7 days. Suppressed COX-2 and 5-LOX. Dose: 100mg and 250mg tested.

---

N29 — GLA (Gamma-Linolenic Acid — Feline)

Citations: 3 | Feline-specific: 3 | Translational: 0 Evidence types: clinical_trial, mechanistic Species coverage: cat

1. Harvey RG. Effect of varying proportions of evening primrose oil and fish oil on cats with miliary dermatitis. Vet Rec. 1993.

   • Type: clinical_trial | Species: cat | Feline-specific: Yes | Tags: GLA, evening_primrose_oil, dermatitis, PGE1
   • Feline miliary dermatitis treated with evening primrose oil (GLA source). GLA bypasses delta-6 desaturase bottleneck in cats, providing direct DGLA→PGE1 anti-inflammatory pathway.

2. Rivers JPW, Sinclair AJ, Crawford MA. Inability of the cat to desaturate essential fatty acids. Nature. 1975. PMID: 1143315

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: delta-6-desaturase, ALA, essential_fatty_acids
   • Landmark: cats lack delta-6 desaturase activity — cannot convert ALA→EPA or LA→GLA. Establishes metabolic rationale for preformed GLA supplementation. Cross-ref N15.

3. Trevizan L, de Mello Kessler A, Brenna JT, et al. Maintenance of arachidonic acid and evidence of delta-5 desaturation in cats fed gamma-linolenic and linoleic acid enriched diets. Lipids. 2012. PMID: 22249937

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: GLA, DGLA, arachidonic_acid, delta-5-desaturase
   • Cats fed GLA-enriched diets maintained AA levels. Evidence of delta-5 desaturase activity in cats (DGLA→AA conversion). Cross-ref N31.

---

N30 — Joint & ECM Substrates: LPL-01 Actives (Marine Collagen Peptides, HA, MSM, Beef Gelatin, Bone Broth) and Comparative Context (⊘ Glucosamine/Chondroitin, ⊘ UC-II)

Citations: 4 | Feline-specific: 2 | Translational: 2 Evidence types: clinical_trial, observational, review, systematic_review Species coverage: cat, cat/dog, dog/cat

Formulation status: Marine Collagen Peptides (500mg), HA (50mg), MSM (100mg), Beef Gelatin (200mg), and Bone Broth (100mg) ARE in Pet Gala. ⊘ Glucosamine/Chondroitin and ⊘ UC-II are NOT in LPL-01. Feline note: radiographic OA affects 61–90% of cats over 12; severely under-diagnosed due to pain-hiding behavior.

Biological role:

• Marine Collagen Peptides 500mg (PG active): Hydrolyzed collagen provides pre-formed proline, hydroxyproline, and glycine — the dominant amino acids of Type I/II collagen triple helices. Bypasses rate-limiting proline hydroxylation in cartilage and skin ECM; feline obligate carnivore amino-acid demand is consistent with preformed peptide delivery. Bioactive di/tripeptides (e.g., Pro-Hyp, Hyp-Gly) detected systemically and at chondrocyte sites after oral dosing (cross-species data).
• Hyaluronic Acid 50mg (PG active): Primary glycosaminoglycan of synovial fluid and skin ECM; provides viscoelastic cushioning, binds water for tissue hydration, suppresses CD44-mediated inflammatory signaling in cartilage.
• MSM 100mg (PG active): Organic sulfur donor; sulfur is required for proteoglycan (aggrecan) GAG side-chain synthesis (chondroitin sulfate, keratan sulfate) and for methionine/cysteine-dependent connective-tissue proteins. Anti-inflammatory and analgesic effects documented in human OA.
• Beef Gelatin 200mg (PG active): Partially hydrolyzed Type I collagen; proline-rich collagen precursor matrix; synergistic with marine collagen peptides for broad amino-acid profile.
• Bone Broth 100mg (PG active): Mineral matrix (Ca, P, trace), collagen-derived peptides, and glycosaminoglycan fragments; delivers both ECM substrate and palatability in the obligate carnivore.
• ⊘ Glucosamine/Chondroitin (comparative — NOT in LPL-01): Glucosamine is UDP-GlcNAc precursor for GAG biosynthesis; chondroitin sulfate is a direct cartilage GAG. Two feline RCTs (Vandeweerd 2012; Gruen 2022) and a 2022 meta-analysis showed no feline OA analgesic efficacy; NOT in LPL-01.
• ⊘ UC-II (comparative — NOT in LPL-01): Undenatured type II collagen acts via oral tolerance / Peyer's patch GALT Treg induction (immunological mechanism distinct from substrate delivery of hydrolyzed collagen). Limited feline efficacy data; NOT in LPL-01.

Claims:

• Marine Collagen Peptides 500mg (PG active): pre-formed proline/hydroxyproline/glycine; systemically absorbed bioactive di/tripeptides; ECM substrate for cartilage and skin [B]
• HA 50mg (PG active): synovial viscosupplementation; CD44 anti-inflammatory; skin hydration [B]
• MSM 100mg (PG active): organic sulfur for proteoglycan synthesis; anti-inflammatory [B]
• Beef Gelatin 200mg (PG active): Type I collagen precursor matrix; proline-rich [B]
• Bone Broth 100mg (PG active): mineral matrix + GAG fragments + palatability [C]
• ⊘ Glucosamine/Chondroitin: UDP-GlcNAc precursor; feline OA RCTs negative; NOT in LPL-01 [B — comparative only]
• ⊘ UC-II: oral tolerance / Treg mechanism distinct from hydrolyzed collagen; limited feline data; NOT in LPL-01 [C — comparative only]

Cross-references: N08 (OA organ reserve), N13 (proteostasis/ECM BDC), N04 (inflammaging), N28 (⊘ Boswellia).

1. Vandeweerd JM, Coisnon C, Clegg P, et al. Systematic review of efficacy of nutraceuticals to alleviate clinical signs of osteoarthritis. J Vet Intern Med. 2012. PMID: 22515653

   • Type: systematic_review | Species: cat/dog | Feline-specific: No | Tags: glucosamine, chondroitin, nutraceuticals, OA, systematic_review
   • Systematic review: limited evidence for glucosamine/chondroitin efficacy in feline OA. 2022 meta-analysis recommends against for feline OA pain. Cross-ref N13.

2. Barbeau-Grégoire M, Bhatt T, Bhatt S, et al. Undenatured Type II Collagen (UC-II) in Joint Health and Disease: A Review on the Current Knowledge of Companion Animals. Animals (Basel). 2020. PMC: PMC7222752

   • Type: review | Species: dog/cat | Feline-specific: No | Tags: UC-II, collagen, oral_tolerance, Treg, joint
   • UC-II mechanism: oral tolerance via Peyer's patches induces Treg cells producing anti-inflammatory cytokines. More effective than glucosamine/chondroitin at smaller doses. Limited feline-specific efficacy data.

3. Blair A, Bonavaud S. Palatability and tolerability of a novel joint supplement in the cat. J Feline Med Surg. 2017.

   • Type: clinical_trial | Species: cat | Feline-specific: Yes | Tags: UC-II, palatability, tolerability, feline
   • World Feline Congress 2017 presentation. UC-II-containing supplement was palatable and well-tolerated in cats. No efficacy data reported — palatability study only.

4. Lascelles BDX, Henry JB III, Brown J, et al. Cross-sectional study of the prevalence of radiographic degenerative joint disease in domesticated cats. Vet Surg. 2010. PMID: 20210963

   • Type: observational | Species: cat | Feline-specific: Yes | Tags: OA, prevalence, radiographic, feline
   • 90% prevalence of DJD in cats >12 years. Feline OA massively underdiagnosed due to behavioral masking. Cross-ref N08.

---

N31 — Preformed Arachidonic Acid & Retinol (Obligate-Carnivore Requirements)

Citations: 6 | Feline-specific: 6 | Translational: 0 Evidence types: mechanistic, review Species coverage: cat

1. Morris JG. Idiosyncratic nutrient requirements of cats appear to be diet-induced evolutionary adaptations. Nutr Res Rev. 2002. PMID: 19087401

   • Type: review | Species: cat | Feline-specific: Yes | Tags: obligate_carnivore, arachidonic_acid, retinol, taurine, evolutionary
   • Comprehensive review of feline-specific nutrient requirements as evolutionary adaptations to obligate carnivory. AA, retinol, taurine all required preformed.

2. Pawlosky RJ, Barnes A, Salem N Jr. Essential fatty acid metabolism in the feline: relationship between liver and brain production of long-chain polyunsaturated fatty acids. J Lipid Res. 1994. PMID: 8642437

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: arachidonic_acid, PUFA, liver, brain, fatty_acid_metabolism
   • Characterizes feline PUFA metabolism. Liver-brain axis for long-chain PUFA production. AA metabolism in cats differs fundamentally from omnivores.

3. Trevizan L, de Mello Kessler A, Brenna JT, et al. Maintenance of arachidonic acid and evidence of delta-5 desaturation in cats. Lipids. 2012. PMID: 22249937

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: arachidonic_acid, delta-5-desaturase, DGLA, GLA
   • Cats maintain AA levels when fed GLA-enriched diets. Delta-5 desaturase present (DGLA→AA). Cross-ref N29.

4. Schweigert FJ, Raila J, Wichert B, Kienzle E. Cats absorb beta-carotene, but it is not converted to vitamin A. J Nutr. 2002. PMID: 12042471

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: beta-carotene, retinol, vitamin_A, BCO1
   • Classic demonstration: oral beta-carotene increased plasma carotenoids but not retinyl esters. BCO1 dioxygenase absent or grossly deficient in cats. Preformed retinol required.

5. Green AS, Tang G, Lango J, et al. Domestic cats convert [2H8]-beta-carotene to [2H4]-retinol following a single oral dose. J Nutr. 2012. PMID: 21797934

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: beta-carotene, retinol, isotope, BCO1, conversion
   • Updated finding using isotope labeling: cats CAN convert beta-carotene to retinol, but conversion is extremely limited. Insufficient to meet vitamin A requirements — preformed retinol remains essential.

6. Morris JG. Cats discriminate between cholecalciferol and ergocalciferol. J Anim Physiol Anim Nutr. 2004. PMID: 15059237

   • Type: review | Species: cat | Feline-specific: Yes | Tags: vitamin_A, arachidonic_acid, essential_nutrients, obligate_carnivore
   • Comprehensive feline nutrient requirements including AA essentiality and preformed vitamin A. Cats require animal-source nutrients due to multiple metabolic limitations.

---

Tier E — Cross-cutting & Methodology

N32 — BDC Scoring Methodology (Feline-Specific Ceilings & Glucuronidation Cost)

Citations: 4 | Feline-specific: 4 | Translational: 0 Evidence types: mechanistic, review Species coverage: cat, cat/dog, cat/felidae

1. Court MH, Greenblatt DJ. Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms. Pharmacogenetics. 2000. PMID: 10862526

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: UGT1A6, pseudogene, glucuronidation, pharmacogenetics
   • Foundational: UGT1A6 is a pseudogene in cats. Only 2 functional UGT1A isoforms (UGT1A1, UGT1A2). Molecular basis for glucuronidation deficiency that drives 4-point BDC gap.

2. Court MH. Feline drug metabolism and disposition: pharmacokinetic evidence for species differences and molecular mechanisms. Vet Clin North Am Small Anim Pract. 2013. PMID: 23890237

   • Type: review | Species: cat | Feline-specific: Yes | Tags: feline_PK, glucuronidation, drug_metabolism, UGT
   • Comprehensive feline PK review. Glucuronidation deficiency not generalized — structure-dependent. GSH conjugation elevated as compensatory pathway. Cross-ref N02.

3. Shrestha B, Reed JM, Engenheiro B, et al. Evolution of a major drug metabolizing enzyme defect in the domestic cat and other Felidae: phylogenetic timing and the role of hypercarnivory. PLoS One. 2011. PMC: PMC3043080

   • Type: mechanistic | Species: cat/felidae | Feline-specific: Yes | Tags: UGT1A6, evolution, hypercarnivory, pseudogene, phylogenetics
   • UGT1A6 pseudogene fixation estimated 35-11 MYA across all extant Felidae. Hypercarnivory reduced exposure to plant phenolics, making UGT1A6 dispensable. Recapitulated in other hypercarnivore lineages.

4. Kondo M, et al. Comparing the glucuronidation capacity of the feline liver with substrate-specific glucuronidation in dogs. J Vet Pharmacol Ther. 2013. PMID: 23888985

   • Type: mechanistic | Species: cat/dog | Feline-specific: Yes | Tags: glucuronidation, UGT, feline_liver, microsomes, dog_comparison
   • Feline hepatic microsomes showed extremely low naphthol-1-glucuronide, estradiol-17-glucuronide, and morphine-3-glucuronide formation vs dogs. Confirms absent functional UGT1A6 and UGT2B7.

---

N33 — Formulation Crosswalk & Multi-System Architecture (Feline)

Citations: 5 | Feline-specific: 4 | Translational: 1 Evidence types: guideline, observational, review Species coverage: cat, mixed

Biological role — Cross-system cascade (feline-adapted): Aging in cats proceeds along a tightly coupled cascade: (1) metabolic dysregulation (obligate-carnivore mTOR tone, absent hepatic glucokinase, obesity-driven insulin resistance) feeds into (2) inflammaging (NF-κB tone, Th2/eosinophilic bias, chronic renal tubulointerstitial nephritis, gingivostomatitis, atopy), which amplifies (3) oxidative stress (carnivore-elevated Phase II GSH burden, 8 reactive hemoglobin sulfhydryls, renal Cu/Zn deficit, limited Nrf2 substrate provision), triggering (4) cellular senescence (renal p16/SA-β-gal, telomere shortening, SASP amplifying inflammaging in feedback), alongside (5) genomic/epigenetic drift (methylation-clock acceleration, FeLV-type insertional risk, one-carbon limitation) — all converging on (6) organ reserve collapse (CKD, HCM, OA, FCDS, hepatic lipidosis). The feline cascade is distinguished from canine/human by obligate-carnivore metabolic constraints, UGT1A6 pseudogene limiting polyphenol clearance, zero ALA→EPA conversion requiring preformed EPA/DHA, and an elevated per-mg potency of marine omega-3 as a consequence.

LPL-01 feline multi-system coverage summary:

• Hollywood Elixir (HE) primary coverage:
  • System 1 — NAD+/sirtuin/nutrient-sensing: NR 60mg (NAD+ precursor → SIRT1/3/6 activation); B3/Niacin 2mg (alternate NAD+ input); B2/Riboflavin 0.5mg (FAD cofactor upstream of NAD+ cycling); B6 1mg and B12 0.25mg (one-carbon/methionine→SAMe→methylation).
  • System 2 — NF-κB / innate immune / inflammaging: Resveratrol 15mg (SIRT1/NF-κB), Quercetin 25mg (NF-κB/NLRP3/mast-cell stabilization), Beta Glucans 50mg (trained-immunity/dectin-1), Reishi 25mg (β-glucan and triterpene immunomodulation), Spirulina 50mg (phycocyanin anti-inflammatory).
  • System 3 — multi-compartment antioxidant defense: Glutathione 50mg (core GSH pool), Astaxanthin 2mg (mitochondrial-targeted; HDL-transported in cats; cardiolipin-adjacent), Vitamin C 10mg (aqueous ROS; regenerates Vitamin E), Vitamin E 15 IU (lipid-phase peroxyl-radical termination), Quercetin 25mg (peroxyl scavenger, metal chelator), Spirulina 50mg and Blueberry Powder 50mg (anthocyanin/carotenoid polyphenols).
  • System 4 — cellular senescence (indirect upstream): SIRT-mediated damage attenuation, Nrf2/GSH-mediated ROS suppression, Quercetin mild-senolytic at maintenance doses (anti-inflammaging upstream).
  • System 5 — genomic & epigenetic integrity: NR 60mg feeds PARP and sirtuin DNA-repair enzymes; B6/B12/Riboflavin one-carbon support for DNA methylation; Whey Protein Isolate 250mg (cysteine donor → GSH → DNA/protein protection).
• Pet Gala (PG) primary coverage:
  • System 2 — EPA/DHA resolvin-driven inflammaging: Omega 3-6-9 blend 150mg (EPA/DHA + GLA + LA) — Grade [A] feline evidence; elevated per-mg potency in cats due to zero ALA→EPA conversion. Omega-7 50mg (palmitoleic acid, hepatic lipid metabolism).
  • System 3 — Zn/SOD antioxidant axis: Zinc (chelated) 1.5mg (Cu/Zn-SOD cofactor; metallothionein; addresses feline renal Cu/Zn deficit).
  • System 5 — zinc DNA repair: Zinc-finger DNA repair enzymes, PARP-adjacent zinc-binding domains.
  • System 6 — renal/cardiac/joint/skin organ reserve: EPA/DHA (renoprotective SDMA/UPC — Grade [A]; cardiac cardiolipin remodeling); L-Carnitine 20mg (β-oxidation; hepatic lipidosis prevention); ECM stack — Marine Collagen Peptides 500mg, HA 50mg, MSM 100mg, Beef Gelatin 200mg, Bone Broth 100mg, Biotin 50mcg, Silica 10mg, Ceramides 8mg (joint, skin/coat, barrier).

Cross-system synergies (HE + PG complementary):

1. EPA/DHA (PG) + Quercetin (HE): dual resolvin-driven resolution of inflammation + NF-κB/NLRP3 inhibition suppresses both initiation and persistence phases of feline inflammaging.
2. Glutathione (HE) + Zinc/SOD (PG): complementary front-line antioxidant defense — SOD dismutates O2•⁻ to H2O2, then GSH-GPx removes H2O2; addresses feline renal Cu/Zn deficit and GSH-Phase II burden simultaneously.
3. NR/B-complex (HE) + L-Carnitine (PG): NAD+-driven β-oxidation flux — NR raises cellular NAD+, L-carnitine shuttles long-chain fatty acids into mitochondria; synergy for hepatic lipidosis prevention in the carnivore.
4. Marine Collagen/MSM/HA (PG) + Resveratrol/Quercetin (HE): ECM substrate delivery paired with NF-κB/MMP suppression for feline OA support (where 61–90% of cats >12 have radiographic OA).
5. Astaxanthin (HE) + EPA/DHA (PG): mitochondrial-localized carotenoid (40–50% of leukocyte astaxanthin in feline mitochondria) paired with cardiolipin-remodeling omega-3 — lipid-phase mitochondrial membrane resilience.
6. Whey Protein Isolate (HE) + Marine Collagen/Gelatin/Bone Broth (PG): broad amino-acid coverage including cysteine (GSH substrate), branched-chain (mTOR-compatible muscle protein synthesis), and preformed proline/hydroxyproline/glycine (ECM) — addresses elevated feline amino-acid demand across aging.
7. B12/B6/Folate-equivalent methyl donors (HE) + Zinc (PG): one-carbon methylation substrate paired with zinc-dependent methyltransferase/DNA-repair enzyme cofactor support for genomic/epigenetic integrity.

Claims (HE/PG attribution):

• Metabolic/NAD+: NR 60mg (HE), B2/B3/B6/B12 (HE) [A/B]
• Inflammaging: EPA/DHA (PG — Grade [A] feline renoprotective), Resveratrol/Quercetin/Beta-Glucans/Reishi/Spirulina (HE) [B]
• Oxidative defense: Glutathione/Astaxanthin/Vit C/Vit E/Quercetin/Spirulina/Blueberry (HE); Zinc-SOD (PG) [B]
• Senescence (upstream): SIRT1 via Resveratrol + NR (HE); Quercetin mild-senolytic (HE) [C]
• Genomic/epigenetic: NR-PARP (HE); B-vitamin methylation (HE); Zinc DNA-repair (PG) [B/C]
• Organ reserve: EPA/DHA renal + cardiac (PG — Grade [A]); L-Carnitine hepatic (PG); ECM stack joint/skin (PG) [A/B]

Cross-references: N01 (baseline hierarchy), N03 (System 1 nutrient sensing), N04 (System 2 inflammaging), N05 (System 3 oxidative), N06 (System 4 senescence), N07 (System 5 genomic/epigenetic), N08 (System 6 organ reserve), N09 (mitochondrial BDC), N10 (oxidative defense BDC), N11 (inflammaging BDC), N12 (nutrient-sensing/autophagy BDC), N13 (proteostasis/ECM BDC), N14 (genomic stability BDC), N15 (EPA/DHA), N17 (B-vitamins), N18 (GSH; ⊘ NAC; ⊘ SAMe), N22 (Zinc; ⊘ Se/Cu/Mn), N23 (L-Carnitine), N24 (⊘ MCT), N25 (⊘ Sulforaphane), N26 (⊘ Spermidine), N27 (⊘ Prebiotics), N28 (⊘ Boswellia), N30 (Joint & ECM), N32 (BDC scoring/glucuronidation), N35 (renal aging), N36 (feline metabolic constraints), N37 (⊘ Curcumin/⊘ Fisetin + Quercetin HE active), N38 (evidence gaps).

1. Brown CA, Elliott J, Schmiedt CW, Brown SA. Chronic kidney disease in aged cats: clinical features, morphology, and proposed pathogeneses. Vet Pathol. 2016. PMID: 26869151

   • Type: review | Species: cat | Feline-specific: Yes | Tags: CKD, tubulointerstitial_nephritis, aging, morphology, pathogenesis
   • CKD driven by chronic tubulointerstitial nephritis of uncertain etiology. Inflammaging→renal cascade is the defining feline geriatric pathway. Cross-ref N01, N35.

2. Reynolds BS, Lefebvre HP. Feline CKD: pathophysiology and risk factors — what do we know?. J Feline Med Surg. 2013. PMID: 23999182

   • Type: review | Species: cat | Feline-specific: Yes | Tags: CKD, pathophysiology, risk_factors, aging
   • CKD affects 30-40% of cats >10y. Multiple risk factors including aging, ischemia, phosphorus overload. Etiology unknown in majority of cases.

3. Sparkes AH, Caney S, Chalhoub S, et al. ISFM consensus guidelines on the diagnosis and management of feline chronic kidney disease. J Feline Med Surg. 2016. PMID: 26936494 | PMC: PMC11148907

   • Type: guideline | Species: cat | Feline-specific: Yes | Tags: CKD, ISFM, guidelines, IRIS, phosphorus, renal_diet
   • ISFM consensus: phosphorus restriction and renal diets extend survival in CKD Stages 2-3 — strongest evidence-backed nutritional intervention in feline medicine. IRIS staging framework.

4. Tarkosova D, Story MM, Rand JS, Morton JM. Strong associations of nine-point body condition scoring with survival and lifespan in cats. J Feline Med Surg. 2024. PMC: PMC11104206

   • Type: observational | Species: cat | Feline-specific: Yes | Tags: BCS, obesity, metabolic, lifespan, survival
   • BCS strongly predicts survival. Metabolic dysregulation→inflammaging cascade: obesity promotes insulin resistance and inflammatory adipokines. Cross-ref N01.

5. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023. PMID: 36599349 | DOI: 10.1016/j.cell.2022.11.001

   • Type: review | Species: mixed | Feline-specific: No | Tags: hallmarks_of_aging, geroscience, framework, multi-system, translational
   • Updated 2023 twelve-hallmarks framework (genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, dysbiosis). Foundational cross-system cascade framework adapted here for feline biology. Cross-ref N01, N03–N08, N38.

---

N34 — Boundary Statements (Nutrition vs Veterinary Medicine — Feline)

Citations: 3 | Feline-specific: 3 | Translational: 0 Evidence types: clinical, guideline Species coverage: cat

1. Sparkes AH, Caney S, Chalhoub S, et al. ISFM consensus guidelines on the diagnosis and management of feline chronic kidney disease. J Feline Med Surg. 2016. PMID: 26936494

   • Type: guideline | Species: cat | Feline-specific: Yes | Tags: CKD, management, nutrition_boundary, veterinary
   • CKD management requires veterinary supervision. Nutritional support ≠ treatment for Stages 3-4. Renal prescription diets are veterinary interventions. Cross-ref N33.

2. Ray M, Carney HC, Boynton B, et al. 2021 AAFP Feline Senior Care Guidelines. J Feline Med Surg. 2021. PMID: 34167339

   • Type: guideline | Species: cat | Feline-specific: Yes | Tags: AAFP, senior_care, guidelines, screening
   • AAFP guidelines delineate nutritional support vs veterinary medical care for senior cats. Screening protocols, disease management boundaries. Cross-ref N01.

3. Pion PD, Kittleson MD, Rogers QR, Morris JG. Myocardial failure in cats associated with low plasma taurine: a reversible cardiomyopathy. Science. 1987. PMID: 3616627

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: taurine, DCM, HCM, boundary, cardiomyopathy
   • Taurine-DCM is reversible deficiency cardiomyopathy. HCM is a fundamentally different disease — taurine supplementation does not treat HCM. Critical boundary statement. Cross-ref N09, N16.

---

N35 — Renal Aging as the Defining Feline Geriatric Challenge

Citations: 6 | Feline-specific: 6 | Translational: 0 Evidence types: clinical, clinical_trial, guideline, observational, review Species coverage: cat

1. Brown CA, Elliott J, Schmiedt CW, Brown SA. Chronic kidney disease in aged cats: clinical features, morphology, and proposed pathogeneses. Vet Pathol. 2016. PMID: 26869151

   • Type: review | Species: cat | Feline-specific: Yes | Tags: CKD, tubulointerstitial_nephritis, aging, nephron_loss
   • CKD is most common metabolic disease in cats. Chronic tubulointerstitial nephritis is the common final outcome. Nephrons do not regenerate. Cross-ref N33.

2. Hall JA, Yerramilli M, Obare E, et al. Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in cats with chronic kidney disease. J Vet Intern Med. 2014. PMID: 25231385

   • Type: clinical | Species: cat | Feline-specific: Yes | Tags: SDMA, creatinine, CKD, biomarker, early_detection
   • SDMA rises when ~25% function lost vs ~75% for creatinine. Earlier CKD detection enables earlier nutritional intervention. Cross-ref N01.

3. Sparkes AH, Caney S, Chalhoub S, et al. ISFM consensus guidelines on the diagnosis and management of feline chronic kidney disease. J Feline Med Surg. 2016. PMID: 26936494

   • Type: guideline | Species: cat | Feline-specific: Yes | Tags: ISFM, CKD, IRIS_staging, phosphorus, renal_diet
   • IRIS staging system. Phosphorus restriction + renal diets extend survival in CKD Stages 2-3. Strongest evidence-backed nutritional intervention in all feline medicine. Cross-ref N33, N34.

4. White JD, Stevenson M, Malik R, et al. Feline chronic kidney disease: can we move from treatment to prevention?. Vet J. 2011. PMID: 21262581

   • Type: review | Species: cat | Feline-specific: Yes | Tags: CKD, prevention, risk_factors, early_intervention
   • Despite treatment advances, CKD cause unknown in majority. Explores prevention strategies including dietary omega-3, phosphorus management. Cross-ref N15, N33.

5. Finch NC, Syme HM, Elliott J. Longevity and mortality in cats: A single institution necropsy study of 3108 cases (1989-2019). PLoS One. 2022. PMID: 36580443

   • Type: observational | Species: cat | Feline-specific: Yes | Tags: mortality, CKD, longevity, necropsy, leading_cause
   • Renal disease was most common cause of mortality in cats ≥5y, causing >13% of deaths at median age 15. Cross-ref N01.

6. Kobayashi S, Kawarasaki M, Aono A, et al. Renoprotective effects of docosahexaenoic acid in cats with early chronic kidney disease due to polycystic kidney disease: a pilot study. J Feline Med Surg. 2022. PMID: 36383208

   • Type: clinical_trial | Species: cat | Feline-specific: Yes | Tags: DHA, CKD, PKD, renoprotective, omega-3
   • DHA renoprotective in early CKD cats. EPA/DHA→renal protection is the strongest single nutritional-aging pathway in feline medicine. Cross-ref N01, N15.

---

N36 — Feline-Specific Metabolic Constraints (Glucuronidation, Obligate Carnivore, ALA→EPA Conversion)

Citations: 6 | Feline-specific: 6 | Translational: 0 Evidence types: mechanistic, review Species coverage: cat, cat/felidae

1. Court MH, Greenblatt DJ. Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene. Pharmacogenetics. 2000. PMID: 10862526

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: UGT1A6, pseudogene, glucuronidation
   • UGT1A6 pseudogene → limited Phase II glucuronidation. Cross-ref N32.

2. Court MH. Feline drug metabolism and disposition. Vet Clin North Am Small Anim Pract. 2013. PMID: 23890237

   • Type: review | Species: cat | Feline-specific: Yes | Tags: feline_PK, metabolism, glucuronidation, sulfation, GSH
   • Comprehensive feline metabolic constraints review. Low glucokinase, elevated GSH conjugation, narrow Se window. Cross-ref N02, N32.

3. Rivers JPW, Sinclair AJ, Crawford MA. Inability of the cat to desaturate essential fatty acids. Nature. 1975. PMID: 1143315

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: delta-6-desaturase, ALA, EPA, essential_fatty_acids
   • Landmark: zero ALA→EPA conversion in cats. Preformed EPA/DHA required. Cross-ref N15, N29.

4. Schweigert FJ, Raila J, Wichert B, Kienzle E. Cats absorb beta-carotene, but it is not converted to vitamin A. J Nutr. 2002. PMID: 12042471

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: beta-carotene, retinol, BCO1, vitamin_A
   • BCO1 dioxygenase absent/deficient. Preformed retinol required. Cross-ref N31.

5. Shrestha B, Reed JM, Engenheiro B, et al. Evolution of a major drug metabolizing enzyme defect in the domestic cat and other Felidae. PLoS One. 2011. PMC: PMC3043080

   • Type: mechanistic | Species: cat/felidae | Feline-specific: Yes | Tags: UGT1A6, evolution, hypercarnivory
   • Evolutionary context: UGT1A6 loss is adaptation to hypercarnivory across Felidae. Cross-ref N32.

6. Morris JG. Idiosyncratic nutrient requirements of cats appear to be diet-induced evolutionary adaptations. Nutr Res Rev. 2002. PMID: 19087401

   • Type: review | Species: cat | Feline-specific: Yes | Tags: obligate_carnivore, evolutionary, taurine, AA, retinol
   • Comprehensive: all feline-specific nutrient requirements as evolutionary adaptations. Low glucokinase, constitutive gluconeogenesis, essential taurine/AA/retinol. Cross-ref N31.

---

N37 — ⊘ Curcumin and ⊘ Fisetin — NOT in LPL-01 Formulation — Comparative Polyphenol Geroscience Context

Citations: 4 | Feline-specific: 3 | Translational: 1 Evidence types: mechanistic, review Species coverage: cat, cat/felidae, dog/cat

Biological role:

• ⊘ Curcumin (comparative — NOT in LPL-01): Diarylheptanoid from Curcuma longa; NF-κB / IKKβ inhibitor and COX-2 suppressor; mechanistically an anti-inflammaging candidate. Native oral bioavailability is poor in all species, and common human bioavailability enhancers (notably piperine) are contraindicated in cats. Not in LPL-01 by formulation scope.
• ⊘ Fisetin (comparative — NOT in LPL-01): Flavonoid identified as the most potent senolytic in a 10-compound systematic in vitro / in vivo comparison; drives p16INK4a+ / p21+ senescent-cell clearance in rodent models with lifespan and healthspan benefits. Grade [D] in cats — no feline efficacy, safety, or pharmacokinetic data exist. Not in LPL-01 by formulation scope.
• Quercetin 25mg (HE active — IS in Hollywood Elixir for BOTH species including cats): Active LPL-01 ingredient at 25mg/sachet. NF-κB / IKK inhibition; NLRP3 inflammasome suppression; mast-cell membrane stabilization (directly relevant to the Th2/eosinophilic bias of feline atopy, asthma, and gingivostomatitis); peroxyl-radical scavenger and metal chelator; mild senolytic activity at maintenance doses. An active contributor to the inflammaging-resolution, antioxidant, and mild-senolytic arms of the HE Hollywood Elixir program for cats.

Claims:

• ⊘ Curcumin: NF-κB/IKK inhibition; COX-2 suppression; not in LPL-01; bioavailability-limited in cats [C/D]
• ⊘ Fisetin: strongest flavonoid senolytic; p16/p21 clearance; Grade [D] feline; not in LPL-01 [D]
• Quercetin 25mg (HE active): NF-κB/NLRP3 inhibition; mast-cell stabilization; IS in Hollywood Elixir for cats [C/D]

Cross-references: N04 (inflammatory tone — NF-κB, NLRP3, Th2/eosinophilic axis), N05 (oxidative stress — peroxyl/chelation), N06 (cellular senescence — comparative context for ⊘ Fisetin and Quercetin mild-senolytic arm), N11 (inflammaging BDC), N14 (genomic stability BDC).

1. Court MH, Greenblatt DJ. Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene. Pharmacogenetics. 2000. PMID: 10862526

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: UGT1A6, pseudogene, feline_PK
   • Foundational feline PK reference cited in this node for general feline metabolic context. Cross-ref N32, N36.

2. Court MH. Feline drug metabolism and disposition. Vet Clin North Am Small Anim Pract. 2013. PMID: 23890237

   • Type: review | Species: cat | Feline-specific: Yes | Tags: feline_PK, phase_II, metabolism
   • Comprehensive feline PK review. Feline Phase II metabolism is structure-dependent and pathway-diverse (GST, sulfation, conjugation), not globally deficient. Cross-ref N02, N32.

3. Shrestha B, Reed JM, Engenheiro B, et al. Evolution of a major drug metabolizing enzyme defect in the domestic cat and other Felidae. PLoS One. 2011. PMC: PMC3043080

   • Type: mechanistic | Species: cat/felidae | Feline-specific: Yes | Tags: UGT1A6, evolution, Felidae, hypercarnivory
   • Evolutionary context for UGT1A6 loss across Felidae. Cross-ref N32, N36.

4. Kuyinu EL, et al. Senotherapy in veterinary medicine: current evidence and future directions. Front Vet Sci. 2024.

   • Type: review | Species: dog/cat | Feline-specific: No | Tags: senotherapy, senolytic, fisetin, veterinary
   • Veterinary senotherapy review. Discusses fisetin as the most potent flavonoid senolytic in the 10-compound systematic comparison; no feline efficacy, safety, or PK data for fisetin. Cross-ref N06, N14.

---

N38 — Feline Evidence Gaps & Translational Uncertainty

Citations: 5 | Feline-specific: 3 | Translational: 2 Evidence types: RCT, mechanistic, observational, review Species coverage: cat, dog, mixed

1. Kaplan JL, Rivas VN, Stern JA, et al. Delayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trial. J Am Vet Med Assoc. 2023. PMID: 37495229 | PMC: PMC10979416

   • Type: RCT | Species: cat | Feline-specific: Yes | Tags: rapamycin, mTOR, HCM, RAPACAT, cardiac
   • RAPACAT: first mTOR inhibition RCT in cats. Low-dose rapamycin halted LV hypertrophy progression in 43 cats with subclinical HCM. FDA conditional approval March 2025. No feline rapamycin-aging data exists beyond HCM. Cross-ref N12.

2. Raj K, Szladovits B, Haghani A, et al. Epigenetic clock and methylation studies in cats. GeroScience. 2021. PMID: 34463900 | PMC: PMC8599556

   • Type: mechanistic | Species: cat | Feline-specific: Yes | Tags: epigenetic_clock, DNA_methylation, aging, biological_age
   • Landmark: first feline epigenetic clocks. Three clocks (cat-only, dual-species human-cat). R=0.97 for cat blood. Also validated in cheetahs, tigers, lions. Not yet clinically actionable. Cross-ref N07.

3. Hofer SJ, Simon AK, Bergmann M, et al. Mechanisms of spermidine-induced autophagy and geroprotection. Nat Aging. 2022. PMID: 37118547

   • Type: review | Species: mixed | Feline-specific: No | Tags: spermidine, autophagy, evidence_gap, no_feline_data
   • Comprehensive spermidine mechanism review. Zero feline spermidine studies exist. All autophagy-induction evidence translational. Cross-ref N26.

4. Simon AK, Russell EF, Leung LHB, et al. A randomized, controlled clinical trial demonstrates improved owner-assessed cognitive function in senior dogs receiving a senolytic and NAD+ precursor combination. Sci Rep. 2024. PMC: PMC11137034

   • Type: RCT | Species: dog | Feline-specific: No | Tags: NAD+, senolytic, cognitive, canine, no_feline_equivalent
   • Canine NAD+ precursor + senolytic RCT: improved cognition in 70 senior dogs. No feline equivalent exists — no feline NAD+ or cognitive-diet trial at any level. Cross-ref N12.

5. Finch NC, Syme HM, Elliott J. Longevity and mortality in cats: A single institution necropsy study of 3108 cases (1989-2019). PLoS One. 2022. PMID: 36580443

   • Type: observational | Species: cat | Feline-specific: Yes | Tags: longevity, mortality, aging, CKD, evidence_landscape
   • 3108 cat necropsy study. Cats underrepresented in companion-animal aging research relative to population. No feline equivalent of Dog Aging Project exists. Renal diets in CKD are only lifespan-extending intervention with Grade A evidence. Cross-ref N01, N35.

---